<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="pt" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id><journal-id journal-id-type="iso-abbrev">Arq Bras Cardiol</journal-id><journal-id journal-id-type="publisher-id">abc</journal-id><journal-title-group><journal-title>Arquivos Brasileiros de Cardiologia</journal-title></journal-title-group><issn pub-type="ppub">0066-782X</issn><issn pub-type="epub">1678-4170</issn><publisher><publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40172433</article-id><article-id pub-id-type="pmc">PMC12013737</article-id>
<article-id pub-id-type="other">00303</article-id><article-id pub-id-type="doi">10.36660/abc.20240761</article-id><article-categories><subj-group subj-group-type="heading"><subject>Artigo Original</subject></subj-group></article-categories><title-group><article-title>Revis&#x000e3;o Sistem&#x000e1;tica sobre a Efic&#x000e1;cia de Metas Intensivas do Tratamento Anti-Hipertensivo: Recomenda&#x000e7;&#x000e3;o da Sociedade Brasileira de Cardiologia (SBC)</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7040-396X</contrib-id><name><surname>Brand&#x000e3;o</surname><given-names>Andr&#x000e9;a Araujo</given-names></name><role>Concep&#x000e7;&#x000e3;o e desenho da pesquisa</role><role>Obten&#x000e7;&#x000e3;o de dados</role><role>An&#x000e1;lise e interpreta&#x000e7;&#x000e3;o dos dados</role><role>Reda&#x000e7;&#x000e3;o do manuscrito e Revis&#x000e3;o cr&#x000ed;tica do manuscrito quanto ao conte&#x000fa;do</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9490-7997</contrib-id><name><surname>Rodrigues</surname><given-names>Cibele Isaac Saad</given-names></name><role>Concep&#x000e7;&#x000e3;o e desenho da pesquisa</role><role>Obten&#x000e7;&#x000e3;o de dados</role><role>An&#x000e1;lise e interpreta&#x000e7;&#x000e3;o dos dados</role><role>Reda&#x000e7;&#x000e3;o do manuscrito e Revis&#x000e3;o cr&#x000ed;tica do manuscrito quanto ao conte&#x000fa;do</role><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4865-6442</contrib-id><name><surname>Bortolotto</surname><given-names>Luiz Aparecido</given-names></name><role>Concep&#x000e7;&#x000e3;o e desenho da pesquisa</role><role>Obten&#x000e7;&#x000e3;o de dados</role><role>An&#x000e1;lise e interpreta&#x000e7;&#x000e3;o dos dados</role><role>Reda&#x000e7;&#x000e3;o do manuscrito e Revis&#x000e3;o cr&#x000ed;tica do manuscrito quanto ao conte&#x000fa;do</role><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9901-6421</contrib-id><name><surname>Luna</surname><given-names>Leonardo Castro</given-names></name><role>Concep&#x000e7;&#x000e3;o e desenho da pesquisa</role><role>Obten&#x000e7;&#x000e3;o de dados</role><role>An&#x000e1;lise e interpreta&#x000e7;&#x000e3;o dos dados</role><role>Reda&#x000e7;&#x000e3;o do manuscrito e Revis&#x000e3;o cr&#x000ed;tica do manuscrito quanto ao conte&#x000fa;do</role><role>An&#x000e1;lise estat&#x000ed;stica</role><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9487-6139</contrib-id><name><surname>Barros</surname><given-names>Bruno Monteiro</given-names></name><role>Concep&#x000e7;&#x000e3;o e desenho da pesquisa</role><role>Obten&#x000e7;&#x000e3;o de dados</role><role>An&#x000e1;lise e interpreta&#x000e7;&#x000e3;o dos dados</role><role>Reda&#x000e7;&#x000e3;o do manuscrito e Revis&#x000e3;o cr&#x000ed;tica do manuscrito quanto ao conte&#x000fa;do</role><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0797-572X</contrib-id><name><surname>Neves</surname><given-names>Mario Fritsch Toros</given-names></name><role>Concep&#x000e7;&#x000e3;o e desenho da pesquisa</role><role>Obten&#x000e7;&#x000e3;o de dados</role><role>An&#x000e1;lise e interpreta&#x000e7;&#x000e3;o dos dados</role><role>Reda&#x000e7;&#x000e3;o do manuscrito e Revis&#x000e3;o cr&#x000ed;tica do manuscrito quanto ao conte&#x000fa;do</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7368-4704</contrib-id><name><surname>Moura</surname><given-names>Ana Fl&#x000e1;via de Souza</given-names></name><role>Concep&#x000e7;&#x000e3;o e desenho da pesquisa</role><role>Obten&#x000e7;&#x000e3;o de dados</role><role>An&#x000e1;lise e interpreta&#x000e7;&#x000e3;o dos dados</role><role>Reda&#x000e7;&#x000e3;o do manuscrito e Revis&#x000e3;o cr&#x000ed;tica do manuscrito quanto ao conte&#x000fa;do</role><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3655-4761</contrib-id><name><surname>Plavnik</surname><given-names>Frida Liane</given-names></name><role>Concep&#x000e7;&#x000e3;o e desenho da pesquisa</role><role>Obten&#x000e7;&#x000e3;o de dados</role><role>An&#x000e1;lise e interpreta&#x000e7;&#x000e3;o dos dados</role><role>Reda&#x000e7;&#x000e3;o do manuscrito e Revis&#x000e3;o cr&#x000ed;tica do manuscrito quanto ao conte&#x000fa;do</role><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2081-6846</contrib-id><name><surname>Drager</surname><given-names>Luciano Ferreira</given-names></name><role>Concep&#x000e7;&#x000e3;o e desenho da pesquisa</role><role>Obten&#x000e7;&#x000e3;o de dados</role><role>An&#x000e1;lise e interpreta&#x000e7;&#x000e3;o dos dados</role><role>Reda&#x000e7;&#x000e3;o do manuscrito e Revis&#x000e3;o cr&#x000ed;tica do manuscrito quanto ao conte&#x000fa;do</role><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Moreira</surname><given-names>Osni</given-names><suffix>Filho</suffix></name><role>Concep&#x000e7;&#x000e3;o e desenho da pesquisa</role><role>Obten&#x000e7;&#x000e3;o de dados</role><role>An&#x000e1;lise e interpreta&#x000e7;&#x000e3;o dos dados</role><role>Reda&#x000e7;&#x000e3;o do manuscrito e Revis&#x000e3;o cr&#x000ed;tica do manuscrito quanto ao conte&#x000fa;do</role><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1265-1930</contrib-id><name><surname>de Souza</surname><given-names>Weimar Kunz Sebba Barroso</given-names></name><role>Concep&#x000e7;&#x000e3;o e desenho da pesquisa</role><role>Obten&#x000e7;&#x000e3;o de dados</role><role>An&#x000e1;lise e interpreta&#x000e7;&#x000e3;o dos dados</role><role>Reda&#x000e7;&#x000e3;o do manuscrito e Revis&#x000e3;o cr&#x000ed;tica do manuscrito quanto ao conte&#x000fa;do</role><xref rid="aff8" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Nadruz</surname><given-names>Wilson</given-names></name><role>Concep&#x000e7;&#x000e3;o e desenho da pesquisa</role><role>Obten&#x000e7;&#x000e3;o de dados</role><role>An&#x000e1;lise e interpreta&#x000e7;&#x000e3;o dos dados</role><role>Reda&#x000e7;&#x000e3;o do manuscrito e Revis&#x000e3;o cr&#x000ed;tica do manuscrito quanto ao conte&#x000fa;do</role><xref rid="aff9" ref-type="aff">
<sup>9</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<institution content-type="orgdiv1">Faculdade de Ci&#x000ea;ncias M&#x000e9;dicas</institution>
<institution content-type="orgname">Universidade do Estado do Rio de Janeiro</institution>
<addr-line>
<named-content content-type="city">Rio de Janeiro</named-content>
<named-content content-type="state">RJ</named-content>
</addr-line>
<country country="BR">Brasil</country>
<institution content-type="original">Faculdade de Ci&#x000ea;ncias M&#x000e9;dicas &#x02013; Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ &#x02013; Brasil</institution>
</aff><aff id="aff2">
<label>2</label>
<institution content-type="orgname">Pontif&#x000ed;cia Universidade Cat&#x000f3;lica de S&#x000e3;o Paulo</institution>
<addr-line>
<named-content content-type="city">Sorocaba</named-content>
<named-content content-type="state">SP</named-content>
</addr-line>
<country country="BR">Brasil</country>
<institution content-type="original">Pontif&#x000ed;cia Universidade Cat&#x000f3;lica de S&#x000e3;o Paulo, Sorocaba, SP &#x02013; Brasil</institution>
</aff><aff id="aff3">
<label>3</label>
<institution content-type="orgdiv1">Instituto do Cora&#x000e7;&#x000e3;o do Hospital das Cl&#x000ed;nicas</institution>
<institution content-type="orgdiv2">Faculdade de Medicina</institution>
<institution content-type="orgname">Universidade de S&#x000e3;o Paulo</institution>
<addr-line>
<named-content content-type="city">S&#x000e3;o Paulo</named-content>
<named-content content-type="state">SP</named-content>
</addr-line>
<country country="BR">Brasil</country>
<institution content-type="original">Instituto do Cora&#x000e7;&#x000e3;o do Hospital das Cl&#x000ed;nicas da Faculdade de Medicina da Universidade de S&#x000e3;o Paulo, S&#x000e3;o Paulo, SP &#x02013; Brasil</institution>
</aff><aff id="aff4">
<label>4</label>
<institution content-type="orgname">Instituto Nacional de Cardiologia</institution>
<addr-line>
<named-content content-type="city">Rio de Janeiro</named-content>
<named-content content-type="state">RJ</named-content>
</addr-line>
<country country="BR">Brasil</country>
<institution content-type="original">Instituto Nacional de Cardiologia, Rio de Janeiro, RJ &#x02013; Brasil</institution>
</aff><aff id="aff5">
<label>5</label>
<institution content-type="orgname">Escola Bahiana de Medicina e Sa&#x000fa;de P&#x000fa;blica</institution>
<addr-line>
<named-content content-type="city">Salvador</named-content>
<named-content content-type="state">BA</named-content>
</addr-line>
<country country="BR">Brasil</country>
<institution content-type="original">Escola Bahiana de Medicina e Sa&#x000fa;de P&#x000fa;blica, Salvador, BA &#x02013; Brasil</institution>
</aff><aff id="aff6">
<label>6</label>
<institution content-type="orgname">Hospital Alem&#x000e3;o Oswaldo Cruz</institution>
<addr-line>
<named-content content-type="city">S&#x000e3;o Paulo</named-content>
<named-content content-type="state">SP</named-content>
</addr-line>
<country country="BR">Brasil</country>
<institution content-type="original">Hospital Alem&#x000e3;o Oswaldo Cruz, S&#x000e3;o Paulo, SP &#x02013; Brasil</institution>
</aff><aff id="aff7">
<label>7</label>
<institution content-type="orgname">Cl&#x000ed;nica Gapski Moreira</institution>
<addr-line>
<named-content content-type="city">Curitiba</named-content>
<named-content content-type="state">PR</named-content>
</addr-line>
<country country="BR">Brasil</country>
<institution content-type="original">Cl&#x000ed;nica Gapski Moreira, Curitiba, PR &#x02013; Brasil</institution>
</aff><aff id="aff8">
<label>8</label>
<institution content-type="orgname">Universidade Federal de Goi&#x000e1;s</institution>
<addr-line>
<named-content content-type="city">Goi&#x000e2;nia</named-content>
<named-content content-type="state">GO</named-content>
</addr-line>
<country country="BR">Brasil</country>
<institution content-type="original">Universidade Federal de Goi&#x000e1;s, Goi&#x000e2;nia, GO &#x02013; Brasil</institution>
</aff><aff id="aff9">
<label>9</label>
<institution content-type="orgdiv1">Faculdade de Ci&#x000ea;ncias M&#x000e9;dicas</institution>
<institution content-type="orgname">UNICAMP</institution>
<addr-line>
<named-content content-type="city">Campinas</named-content>
<named-content content-type="state">SP</named-content>
</addr-line>
<country country="BR">Brasil</country>
<institution content-type="original">Faculdade de Ci&#x000ea;ncias M&#x000e9;dicas, Universidade Estadual de Campinas (UNICAMP), Campinas, SP &#x02013; Brasil</institution>
</aff><author-notes><corresp id="c01">
<label>Correspond&#x000ea;ncia</label>: Andr&#x000e9;a Araujo Brand&#x000e3;o &#x02022; Universidade do Estado do Rio de Janeiro &#x02013; Av. 28 de Setembro, 77. CEP 20551-030, Vila Isabel, Rio de Janeiro, RJ &#x02013; Brasil E-mail: <email>andreaaraujobrandao@gmail.com</email>
</corresp><fn fn-type="edited-by"><p><bold>Editor respons&#x000e1;vel pela revis&#x000e3;o:</bold> Paulo B. Veiga Jardim</p></fn><fn fn-type="COI-statement"><p><bold>Potencial Conflito de Interesse:</bold> N&#x000e3;o h&#x000e1; conflito com o presente artigo.</p></fn></author-notes><pub-date pub-type="epub"><day>18</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2025</year></pub-date><volume>122</volume><issue>3</issue><elocation-id>e20240761</elocation-id><history><date date-type="received"><day>11</day><month>11</month><year>2024</year></date><date date-type="rev-recd"><day>10</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>10</day><month>1</month><year>2025</year></date></history><permissions><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Este &#x000e9; um artigo de acesso aberto distribu&#x000ed;do sob os termos da licen&#x000e7;a de atribui&#x000e7;&#x000e3;o pelo Creative Commons</license-p></license></permissions><abstract><title>Resumo</title><sec><title>Fundamento</title><p> O controle rigoroso da press&#x000e3;o arterial tem sido investigado como uma estrat&#x000e9;gia para reduzir eventos cardiovasculares graves em pacientes hipertensos. No entanto, ainda existem d&#x000fa;vidas sobre o impacto de metas intensivas de tratamento anti-hipertensivo (meta &#x0003c; 130/80 mmHg) em compara&#x000e7;&#x000e3;o com metas convencionais (&#x02265; 130/80 mmHg) na preven&#x000e7;&#x000e3;o de infarto do mioc&#x000e1;rdio, acidente vascular cerebral, mortalidade e poss&#x000ed;veis eventos adversos do tratamento.</p></sec><sec><title>Objetivo</title><p> Avaliar a efic&#x000e1;cia de metas intensivas de tratamento anti-hipertensivo na redu&#x000e7;&#x000e3;o de eventos cardiovasculares cr&#x000ed;ticos em compara&#x000e7;&#x000e3;o com metas usuais.</p></sec><sec><title>M&#x000e9;todos</title><p> Esta revis&#x000e3;o sistem&#x000e1;tica incluiu ensaios cl&#x000ed;nicos randomizados (ECRs) que compararam metas intensivas de controle da press&#x000e3;o arterial com metas convencionais em adultos com 18 anos ou mais. Foram inclu&#x000ed;dos estudos com pelo menos um dos seguintes desfechos: mortalidade, infarto do mioc&#x000e1;rdio, acidente vascular cerebral, progress&#x000e3;o para doen&#x000e7;a renal cr&#x000f4;nica em est&#x000e1;gios IV ou V, necessidade de di&#x000e1;lise ou transplante renal. As bases de dados Medline, Embase e Cochrane Library foram pesquisadas at&#x000e9; maio de 2024. A avalia&#x000e7;&#x000e3;o do risco de vi&#x000e9;s foi realizada por dois revisores independentes utilizando a ferramenta Risk of Bias 2 (RoB 2) da Colabora&#x000e7;&#x000e3;o Cochrane. A s&#x000ed;ntese dos resultados foi conduzida por meio de metan&#x000e1;lise para o desfecho composto de infarto do mioc&#x000e1;rdio, acidente vascular cerebral e mortalidade por todas as causas. A certeza da evid&#x000ea;ncia cient&#x000ed;fica e a for&#x000e7;a de recomenda&#x000e7;&#x000e3;o seguiram os m&#x000e9;todos propostos pela ferramenta GRADE (Grading of Recommendations Assessment, Development and Evaluation).</p></sec><sec><title>Resultados</title><p> Foram inclu&#x000ed;dos nove ECRs com mais de 34.000 participantes. O tratamento intensivo foi associado a uma redu&#x000e7;&#x000e3;o de 13% nos eventos cardiovasculares. Nos estudos com baixo risco de vi&#x000e9;s, a redu&#x000e7;&#x000e3;o foi de 17%, com alta certeza da evid&#x000ea;ncia. Separadamente, observou-se uma redu&#x000e7;&#x000e3;o significativa nos desfechos de infarto do mioc&#x000e1;rdio e acidente vascular cerebral, mas n&#x000e3;o na mortalidade por todas as causas. Dados limitados foram encontrados sobre a progress&#x000e3;o da doen&#x000e7;a renal e necessidade de di&#x000e1;lise ou transplante renal.</p></sec><sec><title>Conclus&#x000e3;o</title><p> As evid&#x000ea;ncias de alta qualidade sugerem que metas mais intensivas de tratamento anti-hipertensivo reduzem significativamente os eventos cardiovasculares. Contudo, a escolha das metas de tratamento deve ser individualizada, considerando fatores como idade, fragilidade, o risco cardiovascular individual e a possibilidade de eventos adversos. A ades&#x000e3;o ao tratamento &#x000e9; fundamental para o sucesso terap&#x000ea;utico.</p></sec></abstract><abstract abstract-type="graphical"><p>
<fig position="float" id="f01"><label>Figura Central</label><caption><title>: Revis&#x000e3;o Sistem&#x000e1;tica sobre a Efic&#x000e1;cia de Metas Intensivas do Tratamento Anti-Hipertensivo: Recomenda&#x000e7;&#x000e3;o da Sociedade Brasileira de Cardiologia (SBC)</title></caption><graphic xlink:href="0066-782X-abc-122-3-e20240761-gf01" position="float"/><attrib>Heterogeneidade: I<sup>2</sup>= 0%, t<sup>2</sup> = 0,0013, p = 0,60</attrib></fig>
</p></abstract><kwd-group><kwd>Hipertens&#x000e3;o</kwd><kwd>Revis&#x000e3;o Sistem&#x000e1;tica</kwd><kwd>Metan&#x000e1;lise</kwd><kwd>Tratamento Farmacol&#x000f3;gico</kwd></kwd-group><counts><fig-count count="6"/><table-count count="6"/><equation-count count="0"/><ref-count count="40"/></counts></article-meta></front><body><p><bold>Recomenda&#x000e7;&#x000e3;o 1:</bold> A Sociedade Brasileira de Cardiologia recomenda a estrat&#x000e9;gia de metas mais intensivas para o tratamento anti-hipertensivo (valores menores de 130/80 mmHg) para pacientes adultos hipertensos, com o objetivo de reduzir eventos cardiovasculares importantes (infarto do mioc&#x000e1;rdio, acidente vascular cerebral e morte). Esta &#x000e9; uma recomenda&#x000e7;&#x000e3;o forte com uma alta certeza da evid&#x000ea;ncia.</p><p><bold>Recomenda&#x000e7;&#x000e3;o 2:</bold> A Sociedade Brasileira de Cardiologia recomenda a estrat&#x000e9;gia de metas mais intensivas para o tratamento anti-hipertensivo (valores menores de 130/80 mmHg) para pacientes hipertensos idosos (idade &#x0003e; 65 anos), com o objetivo de reduzir eventos cardiovasculares importantes futuros (infarto do mioc&#x000e1;rdio, acidente vascular cerebral e morte). Esta &#x000e9; uma recomenda&#x000e7;&#x000e3;o forte com uma alta certeza da evid&#x000ea;ncia. Esta recomenda&#x000e7;&#x000e3;o deve ser avaliada de forma individualizada quando se tratar de um idoso fr&#x000e1;gil ou com expectativa de vida futura limitada.</p><p><bold>Recomenda&#x000e7;&#x000e3;o 3:</bold> A Sociedade Brasileira de Cardiologia recomenda a estrat&#x000e9;gia de metas mais intensivas para o tratamento anti-hipertensivo (redu&#x000e7;&#x000e3;o adicional de 5 mmHg) para pacientes hipertensos de alto risco cardiovascular que j&#x000e1; estejam dentro da meta de tratamento intensivo (PAS &#x0003c; 130 mmHg), com o objetivo de redu&#x000e7;&#x000e3;o adicional de eventos cardiovasculares importantes futuros (infarto do mioc&#x000e1;rdio, acidente vascular cerebral e morte). Esta &#x000e9; uma recomenda&#x000e7;&#x000e3;o forte com uma alta certeza da evid&#x000ea;ncia.</p><sec sec-type="intro"><title>Introdu&#x000e7;&#x000e3;o</title><p>A hipertens&#x000e3;o arterial (HA) &#x000e9; atualmente um importante desafio de sa&#x000fa;de, que contribui substancialmente para as taxas de doen&#x000e7;as cardiovasculares globalmente. Trata-se de um dos principais fatores de risco para morbidade e mortalidade, afetando mais de um bilh&#x000e3;o de pessoas e sendo respons&#x000e1;vel por aproximadamente 9,4 milh&#x000f5;es de mortes anuais.<sup><xref rid="B1" ref-type="bibr">1</xref></sup> A HA n&#x000e3;o apenas aumenta o risco de complica&#x000e7;&#x000f5;es cardiovasculares, mas tamb&#x000e9;m imp&#x000f5;e uma consider&#x000e1;vel carga econ&#x000f4;mica sobre os sistemas de sa&#x000fa;de, especialmente em pa&#x000ed;ses de baixa e m&#x000e9;dia renda.<sup><xref rid="B2" ref-type="bibr">2</xref></sup> No Brasil, a HA tamb&#x000e9;m &#x000e9; um grande problema de sa&#x000fa;de p&#x000fa;blica, que afeta aproximadamente um ter&#x000e7;o da popula&#x000e7;&#x000e3;o adulta.<sup><xref rid="B3" ref-type="bibr">3</xref></sup> &#x000c9; respons&#x000e1;vel por uma propor&#x000e7;&#x000e3;o significativa de infartos e acidentes vasculares cerebrais, que s&#x000e3;o as principais causas de morte no pa&#x000ed;s.<sup><xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B5" ref-type="bibr">5</xref></sup> A HA tamb&#x000e9;m exerce uma influ&#x000ea;ncia substancial sobre o Sistema &#x000da;nico de Sa&#x000fa;de (SUS), resultando em aumento dos custos de sa&#x000fa;de, consider&#x000e1;vel perda de dias de trabalho e aposentadoria precoce.<sup><xref rid="B6" ref-type="bibr">6</xref></sup> H&#x000e1; uma necessidade crescente de interven&#x000e7;&#x000f5;es eficazes de sa&#x000fa;de p&#x000fa;blica voltadas para a preven&#x000e7;&#x000e3;o, detec&#x000e7;&#x000e3;o precoce e manejo da doen&#x000e7;a.<sup><xref rid="B7" ref-type="bibr">7</xref></sup> Enfrentar esse desafio &#x000e9; crucial para melhorar a sa&#x000fa;de e reduzir os n&#x000ed;veis de doen&#x000e7;as cr&#x000f4;nicas no Brasil.</p><p>O tratamento anti-hipertensivo desempenha papel crucial no manejo da doen&#x000e7;a e na redu&#x000e7;&#x000e3;o do risco associado a eventos cardiovasculares, e normalmente envolve uma combina&#x000e7;&#x000e3;o de interven&#x000e7;&#x000f5;es no estilo de vida com tratamentos farmacol&#x000f3;gicos.<sup><xref rid="B7" ref-type="bibr">7</xref></sup> Atualmente, existe um debate a respeito das metas ideais a serem alcan&#x000e7;adas na HA. As estrat&#x000e9;gias de controle intensivo, que visam metas mais baixas de press&#x000e3;o arterial (PA), mostraram uma redu&#x000e7;&#x000e3;o significativa na incid&#x000ea;ncia de eventos cr&#x000ed;ticos em pacientes de alto risco em estudos cl&#x000ed;nicos como o SPRINT.<sup><xref rid="B8" ref-type="bibr">8</xref></sup> No entanto, essa abordagem tamb&#x000e9;m traz um aumento potencial dos riscos de eventos adversos, como hipotens&#x000e3;o, les&#x000e3;o renal aguda e desequil&#x000ed;brios eletrol&#x000ed;ticos, que podem levar a desfechos desfavor&#x000e1;veis, especialmente em pacientes idosos ou fr&#x000e1;geis.<sup><xref rid="B9" ref-type="bibr">9</xref></sup> Por outro lado, o tratamento convencional, que segue metas de PA mais moderadas, pode n&#x000e3;o proporcionar o mesmo n&#x000ed;vel de prote&#x000e7;&#x000e3;o cardiovascular e renal.<sup><xref rid="B8" ref-type="bibr">8</xref></sup> Essa discuss&#x000e3;o ressalta a import&#x000e2;ncia de tratamentos individualizados, que considerem o estado geral de sa&#x000fa;de do paciente, al&#x000e9;m das comorbidades e a possibilidade de efeitos adversos relacionados ao tratamento.</p><p>Com o objetivo de esclarecer a melhor estrat&#x000e9;gia em rela&#x000e7;&#x000e3;o &#x000e0;s metas de PA em pacientes hipertensos, considerando as melhores evid&#x000ea;ncias cient&#x000ed;ficas atuais, a Sociedade Brasileira de Cardiologia (SBC) desenvolveu uma Recomenda&#x000e7;&#x000e3;o Cl&#x000ed;nica sobre o tema.</p></sec><sec sec-type="methods"><title>M&#x000e9;todos</title><p>Para a realiza&#x000e7;&#x000e3;o da Recomenda&#x000e7;&#x000e3;o Cl&#x000ed;nica, foi realizada uma revis&#x000e3;o sistem&#x000e1;tica. A pergunta de pesquisa estruturada no formato PICO (paciente/popula&#x000e7;&#x000e3;o, interven&#x000e7;&#x000e3;o, compara&#x000e7;&#x000e3;o e desfecho) foi: Em pacientes hipertensos, qual &#x000e9; a diferen&#x000e7;a do tratamento farmacol&#x000f3;gico com metas mais intensivas de controle da PA (&#x0003c; 130/80 mmHg) comparadas a metas de controle habitual (&#x02265; 130/80 mmHg), especificamente em rela&#x000e7;&#x000e3;o a desfechos cr&#x000ed;ticos e importantes, como morte, acidente vascular cerebral, infarto do mioc&#x000e1;rdio, progress&#x000e3;o para insufici&#x000ea;ncia renal est&#x000e1;gio 4 ou 5, necessidade de di&#x000e1;lise ou transplante renal? O protocolo do estudo foi registrado na base de dados PROSPERO, sob o n&#x000fa;mero CRD42024545853.</p><p>A revis&#x000e3;o sistem&#x000e1;tica r&#x000e1;pida, metodologia empregada neste documento, pertence &#x000e0; fam&#x000ed;lia das revis&#x000f5;es sistem&#x000e1;ticas. Trata-se de uma ferramenta desenvolvida na &#x000fa;ltima d&#x000e9;cada com o objetivo de manter o rigor metodol&#x000f3;gico em busca das melhores evid&#x000ea;ncias poss&#x000ed;veis, por&#x000e9;m com modifica&#x000e7;&#x000f5;es que aceleram o tempo de execu&#x000e7;&#x000e3;o. Geralmente, essas revis&#x000f5;es informam sociedades m&#x000e9;dicas ou institui&#x000e7;&#x000f5;es de sa&#x000fa;de sobre as melhores evid&#x000ea;ncias dispon&#x000ed;veis, com base em uma pergunta no formato PICO, de maneira sens&#x000ed;vel, transparente e sistem&#x000e1;tica. Institui&#x000e7;&#x000f5;es de destaque na &#x000e1;rea de metodologia descreveram os m&#x000e9;todos para esse tipo de revis&#x000e3;o sistem&#x000e1;tica.<sup><xref rid="B10" ref-type="bibr">10</xref>-<xref rid="B12" ref-type="bibr">12</xref></sup></p><p>Uma primeira busca por revis&#x000f5;es sistem&#x000e1;ticas sobre a pergunta PICO foi realizada em tr&#x000ea;s bases de dados: Medline, Embase e a Biblioteca Cochrane. Os detalhes das estrat&#x000e9;gias de busca est&#x000e3;o fornecidos no material suplementar (<inline-supplementary-material xlink:href="0066-782X-abc-122-3-e20240761-suppl01.pdf" id="d67e567" content-type="local-data">Tabela S1</inline-supplementary-material>). Dois pesquisadores realizaram, de forma independente, a sele&#x000e7;&#x000e3;o dos estudos e a extra&#x000e7;&#x000e3;o das caracter&#x000ed;sticas basais dos documentos definidos para leitura completa (<inline-supplementary-material xlink:href="0066-782X-abc-122-3-e20240761-suppl01.pdf" id="d67e570" content-type="local-data">Tabelas S2 e S3</inline-supplementary-material>). No entanto, entre as revis&#x000f5;es sistem&#x000e1;ticas encontradas, que cobrem os anos de 2019 a 2024, nenhuma abordou exatamente a quest&#x000e3;o PICO de interesse, exceto pelo documento de Sakima et al.<sup><xref rid="B13" ref-type="bibr">13</xref></sup> Esta publica&#x000e7;&#x000e3;o incluiu buscas por estudos at&#x000e9; mar&#x000e7;o de 2018, recuperando nove artigos que compararam a meta intensiva de PA (&#x0003c; 130/80 mmHg) com a meta usual e avaliaram eventos cardiovasculares como desfecho. A decis&#x000e3;o dos autores foi atualizar a busca dessa revis&#x000e3;o sistem&#x000e1;tica e realizar uma nova metan&#x000e1;lise com os dados extra&#x000ed;dos dos estudos prim&#x000e1;rios.</p><p>Uma segunda busca por ensaios cl&#x000ed;nicos randomizados (ECRs) foi realizada para a atualiza&#x000e7;&#x000e3;o do documento de refer&#x000ea;ncia escolhido, englobando o per&#x000ed;odo de mar&#x000e7;o de 2018 a maio de 2024 nas mesmas bases de dados que a primeira busca. Os detalhes das estrat&#x000e9;gias de busca est&#x000e3;o fornecidos no material suplementar (<inline-supplementary-material xlink:href="0066-782X-abc-122-3-e20240761-suppl01.pdf" id="d67e579" content-type="local-data">Tabela 4S</inline-supplementary-material>). Os artigos selecionados para a revis&#x000e3;o de texto completo foram considerados para inclus&#x000e3;o se atendessem aos seguintes crit&#x000e9;rios: (1) ser um ECR; (2) apresentar estimativas de risco para avaliar o impacto de metas intensivas de PA versus metas usuais de PA; (3) apresentar pelo menos um dos seguintes desfechos descrito numericamente: mortalidade por todas as causas, acidente vascular cerebral, infarto do mioc&#x000e1;rdio e progress&#x000e3;o para insufici&#x000ea;ncia renal est&#x000e1;gio 4 ou 5, necessidade de di&#x000e1;lise ou transplante renal; (4) incluir pacientes com 18 anos ou mais. N&#x000e3;o houve restri&#x000e7;&#x000f5;es de idioma na sele&#x000e7;&#x000e3;o dos estudos.</p><p>Dois pesquisadores foram respons&#x000e1;veis pela sele&#x000e7;&#x000e3;o, extra&#x000e7;&#x000e3;o e avalia&#x000e7;&#x000e3;o da qualidade de todos os artigos finais. A ferramenta RoB 2 (<italic toggle="yes">Risk of Bias 2</italic>) da Colabora&#x000e7;&#x000e3;o Cochrane foi utilizada para a avalia&#x000e7;&#x000e3;o do risco de vi&#x000e9;s.<sup><xref rid="B14" ref-type="bibr">14</xref></sup> A for&#x000e7;a das recomenda&#x000e7;&#x000f5;es e a certeza das evid&#x000ea;ncias foram determinadas de acordo com a metodologia GRADE (<italic toggle="yes">Grading of Recommendations Assessment, Development and Evaluation</italic>)<sup><xref rid="B15" ref-type="bibr">15</xref></sup> (<xref rid="t2" ref-type="table">Tabelas 2</xref> e <xref rid="t3" ref-type="table">3</xref>).Uma descri&#x000e7;&#x000e3;o detalhada da metodologia empregada nesta revis&#x000e3;o sistem&#x000e1;tica pode ser encontrada no material suplementar. O vi&#x000e9;s de publica&#x000e7;&#x000e3;o n&#x000e3;o foi avaliado pela raz&#x000e3;o do n&#x000fa;mero de estudos originais ser menor do que dez.</p><p>As recomenda&#x000e7;&#x000f5;es cl&#x000ed;nicas foram definidas de forma consensual em reuni&#x000e3;o de um Painel de Recomenda&#x000e7;&#x000e3;o formado por profissionais indicados pela SBC. Foi considerado o limiar de 5% como uma diferen&#x000e7;a m&#x000ed;nima importante para a interven&#x000e7;&#x000e3;o ser considerada clinicamente relevante.</p><p>
<table-wrap position="float" id="t2"><label>Tabela 2</label><caption><title>&#x02013; Risco de vi&#x000e9;s dos estudos prim&#x000e1;rios segundo a ferramenta RoB 2.0 da Colabora&#x000e7;&#x000e3;o Cochrane</title></caption><table frame="hsides" rules="groups"><colgroup width="10%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Estudo</th><th rowspan="1" colspan="1">Interven&#x000e7;&#x000e3;o</th><th rowspan="1" colspan="1">Comparador</th><th rowspan="1" colspan="1">Desfecho</th><th rowspan="1" colspan="1">D1</th><th rowspan="1" colspan="1">D2</th><th rowspan="1" colspan="1">D3</th><th rowspan="1" colspan="1">D4</th><th rowspan="1" colspan="1">D5</th><th align="left" style="font-weight:normal" rowspan="1" colspan="1">&#x000a0;</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Schrier</td><td align="center" rowspan="1" colspan="1">TTO Intensivo</td><td align="center" rowspan="1" colspan="1">TTO Usual</td><td align="center" rowspan="1" colspan="1">Eventos CV</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04" position="float"/>
</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04" position="float"/>
</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt05" position="float"/>
</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04" position="float"/>
</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04" position="float"/>
</td><td rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt05a" position="float"/>
</td></tr><tr><td rowspan="1" colspan="1">ESTACIO</td><td align="center" rowspan="1" colspan="1">TTO Intensivo</td><td align="center" rowspan="1" colspan="1">TTO Usual</td><td align="center" rowspan="1" colspan="1">Eventos CV</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04" position="float"/>
</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04" position="float"/>
</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04" position="float"/>
</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt06" position="float"/>
</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04" position="float"/>
</td><td rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt06a" position="float"/>
</td></tr><tr><td rowspan="1" colspan="1">CardioSis</td><td align="center" rowspan="1" colspan="1">TTO Intensivo</td><td align="center" rowspan="1" colspan="1">TTO Usual</td><td align="center" rowspan="1" colspan="1">Eventos CV</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt05" position="float"/>
</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt06" position="float"/>
</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04" position="float"/>
</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt06" position="float"/>
</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt06" position="float"/>
</td><td rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt05a" position="float"/>
</td></tr><tr><td rowspan="1" colspan="1">Appel</td><td align="center" rowspan="1" colspan="1">TTO Intensivo</td><td align="center" rowspan="1" colspan="1">TTO Usual</td><td align="center" rowspan="1" colspan="1">Eventos CV</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt06" position="float"/>
</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt06" position="float"/>
</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04" position="float"/>
</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04" position="float"/>
</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt06" position="float"/>
</td><td rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt06a" position="float"/>
</td></tr><tr><td rowspan="1" colspan="1">ACCORD</td><td align="center" rowspan="1" colspan="1">TTO Intensivo</td><td align="center" rowspan="1" colspan="1">TTO Usual</td><td align="center" rowspan="1" colspan="1">Eventos CV</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04" position="float"/>
</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt06" position="float"/>
</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04" position="float"/>
</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04" position="float"/>
</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04" position="float"/>
</td><td rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04a" position="float"/>
</td></tr><tr><td rowspan="1" colspan="1">SPS3</td><td align="center" rowspan="1" colspan="1">TTO Intensivo</td><td align="center" rowspan="1" colspan="1">TTO Usual</td><td align="center" rowspan="1" colspan="1">Eventos CV</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04" position="float"/>
</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04" position="float"/>
</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt06" position="float"/>
</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04" position="float"/>
</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04" position="float"/>
</td><td rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt06a" position="float"/>
</td></tr><tr><td rowspan="1" colspan="1">SPRINT</td><td align="center" rowspan="1" colspan="1">TTO Intensivo</td><td align="center" rowspan="1" colspan="1">TTO Usual</td><td align="center" rowspan="1" colspan="1">Eventos CV</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04" position="float"/>
</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04" position="float"/>
</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04" position="float"/>
</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04" position="float"/>
</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04" position="float"/>
</td><td rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04a" position="float"/>
</td></tr><tr><td rowspan="1" colspan="1">HOMED-BP</td><td align="center" rowspan="1" colspan="1">TTO Intensivo</td><td align="center" rowspan="1" colspan="1">TTO Usual</td><td align="center" rowspan="1" colspan="1">Eventos CV</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04" position="float"/>
</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt05" position="float"/>
</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt05" position="float"/>
</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04" position="float"/>
</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04" position="float"/>
</td><td rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt05a" position="float"/>
</td></tr><tr><td rowspan="1" colspan="1">STEP - Zhang</td><td align="center" rowspan="1" colspan="1">TTO Intensivo</td><td align="center" rowspan="1" colspan="1">TTO Usual</td><td align="center" rowspan="1" colspan="1">Eventos CV</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04" position="float"/>
</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04" position="float"/>
</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04" position="float"/>
</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04" position="float"/>
</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04" position="float"/>
</td><td rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04a" position="float"/>
</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04" position="float"/>: Baixo Risco; <graphic xlink:href="0066-782X-abc-122-3-e20240761-gt06" position="float"/>: Moderado Risco; <graphic xlink:href="0066-782X-abc-122-3-e20240761-gt05" position="float"/>: Alto Risco. D1: Randomiza&#x000e7;&#x000e3;o; D2: Desvio do TTO; D3: Dados Faltantes; D4: Medida do Desfecho; D5: Sele&#x000e7;&#x000e3;o de Resultados Reportados. CV: cardiovasculares; TTO: tratamento.</p></fn></table-wrap-foot></table-wrap>
</p><p>
<table-wrap position="float" id="t3"><label>Tabela 3</label><caption><title>&#x02013; Sum&#x000e1;rios de resultados (SoF &#x02013; Summary of Findings), de acordo com a metodologia GRADE</title></caption><table frame="hsides" rules="groups"><colgroup width="17%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Desfecho</th><th colspan="2" rowspan="1">Efeito Absoluto (95% CI)</th><th rowspan="2" colspan="1">Efeito Relativo (95% IC)</th><th rowspan="2" colspan="1">N<sup>o</sup> de participantes (estudos)</th><th rowspan="2" colspan="1">Certeza da Evid&#x000ea;ncia</th></tr><tr><th rowspan="1" colspan="1">Risco com o tratamento usual</th><th rowspan="1" colspan="1">Risco com o tratamento intensivo (&#x0003c; 130/80 mmHg)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Eventos CV (Morte, IAM e AVC)</td><td align="center" rowspan="1" colspan="1">89 por 1000</td><td align="center" rowspan="1" colspan="1">77 por 1000</td><td align="center" rowspan="1" colspan="1">RR 0,87 (0,80 a 0,94)</td><td align="center" rowspan="1" colspan="1">32749 (9 ECRs)</td><td align="center" rowspan="1" colspan="1">Alta</td></tr><tr><td rowspan="1" colspan="1">Morte</td><td align="center" rowspan="1" colspan="1">39 por 1000</td><td align="center" rowspan="1" colspan="1">36 por 1000</td><td align="center" rowspan="1" colspan="1">RR 0,93 (0,80 a 1,09)</td><td align="center" rowspan="1" colspan="1">32029 (9 ECRs)</td><td align="center" rowspan="1" colspan="1">Alta</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p>AVC: acidente vascular cerebral; CV: cardiovasculares; ECRs: ensaios cl&#x000ed;nicos randomizados; IAM: infarto agudo do mioc&#x000e1;rdio; N&#x000ba;: n&#x000fa;mero.</p></fn></table-wrap-foot></table-wrap>
</p><p>Todo o projeto foi supervisionado e financiado pela SBC. A elabora&#x000e7;&#x000e3;o da revis&#x000e3;o sistem&#x000e1;tica foi conduzida por uma equipe independente de metodologistas.</p></sec><sec sec-type="results"><title>Resultados</title><p>Os nove artigos inclu&#x000ed;dos na metan&#x000e1;lise de refer&#x000ea;ncia,<sup><xref rid="B13" ref-type="bibr">13</xref></sup> comparando a meta de tratamento anti-hipertensivo intensivo (&#x0003c; 130/80 mmHg) com a meta de tratamento padr&#x000e3;o, foram avaliados para inclus&#x000e3;o nesta nova metan&#x000e1;lise aqui apresentada. Desses, um foi exclu&#x000ed;do por n&#x000e3;o apresentar os riscos relativos de interesse,<sup><xref rid="B16" ref-type="bibr">16</xref></sup> e os oito restantes foram inclu&#x000ed;dos.<sup><xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B17" ref-type="bibr">17</xref>-<xref rid="B23" ref-type="bibr">23</xref></sup></p><p>Como resultado da segunda busca na literatura, que teve como objetivo identificar novos ECRs publicados ap&#x000f3;s mar&#x000e7;o de 2018, foram inicialmente triadas 2.061 cita&#x000e7;&#x000f5;es. Destas, apenas dois estudos foram selecionados para a revis&#x000e3;o de texto completo, resultando na inclus&#x000e3;o de um ECR adicional na metan&#x000e1;lise atualizada,<sup><xref rid="B24" ref-type="bibr">24</xref></sup> e na exclus&#x000e3;o do segundo artigo por n&#x000e3;o ser um ECR original.<sup><xref rid="B25" ref-type="bibr">25</xref></sup></p><p>As principais caracter&#x000ed;sticas dos nove estudos prim&#x000e1;rios inclu&#x000ed;dos nesta metan&#x000e1;lise est&#x000e3;o apresentadas na <xref rid="t1" ref-type="table">Tabela 1</xref>. Todas as caracter&#x000ed;sticas extra&#x000ed;das est&#x000e3;o dispon&#x000ed;veis no material suplementar (<inline-supplementary-material xlink:href="0066-782X-abc-122-3-e20240761-suppl01.pdf" id="d67e1055" content-type="local-data">Tabela 5S</inline-supplementary-material>).</p><p>
<table-wrap position="float" id="t1"><label>Tabela 1</label><caption><title>&#x02013; Caracter&#x000ed;sticas principais dos estudos prim&#x000e1;rios</title></caption><table frame="hsides" rules="groups"><colgroup width="8%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Autor principal</th><th rowspan="1" colspan="1">Ano de Publica&#x000e7;&#x000e3;o</th><th rowspan="1" colspan="1">Caracter&#x000ed;sticas da Popula&#x000e7;&#x000e3;o</th><th rowspan="1" colspan="1">Meta da PA no grupo Intensivo</th><th rowspan="1" colspan="1">PA Sist&#x000f3;lica Basal (mmHg)</th><th rowspan="1" colspan="1">PA Diast&#x000f3;lica Basal (mmHg)</th><th rowspan="1" colspan="1">N&#x000fa;mero de participantes</th><th rowspan="1" colspan="1">Eventos</th><th rowspan="1" colspan="1">Idade M&#x000e9;dia</th><th rowspan="1" colspan="1">Percentual de Mulheres</th><th rowspan="1" colspan="1">Pa&#x000ed;s</th><th rowspan="1" colspan="1">Dados Faltantes n(%)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">#02 Schrier</td><td align="center" rowspan="1" colspan="1">2002</td><td align="center" rowspan="1" colspan="1">Pacientes com diabetes tipo 2 normotensos</td><td align="center" rowspan="1" colspan="1">&#x0003c;130/80 mmHg</td><td align="center" rowspan="1" colspan="1">141,5</td><td align="center" rowspan="1" colspan="1">96</td><td align="center" rowspan="1" colspan="1">480</td><td align="center" rowspan="1" colspan="1">89</td><td align="center" rowspan="1" colspan="1">57</td><td align="center" rowspan="1" colspan="1">49%</td><td align="center" rowspan="1" colspan="1">EUA</td><td align="center" rowspan="1" colspan="1">55(11)</td></tr><tr><td rowspan="1" colspan="1">#3 Estacio</td><td align="center" rowspan="1" colspan="1">2006</td><td align="center" rowspan="1" colspan="1">Pacientes normotensos com diabetes tipo 2 e normo ou microalbumin&#x000fa;ria</td><td align="center" rowspan="1" colspan="1">&#x0003c; 75 mmHg (PAD)</td><td align="center" rowspan="1" colspan="1">126</td><td align="center" rowspan="1" colspan="1">84</td><td align="center" rowspan="1" colspan="1">129</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">56</td><td align="center" rowspan="1" colspan="1">47%</td><td align="center" rowspan="1" colspan="1">EUA</td><td align="center" rowspan="1" colspan="1">10(7)</td></tr><tr><td rowspan="1" colspan="1">#4 CardioSis</td><td align="center" rowspan="1" colspan="1">2009</td><td align="center" rowspan="1" colspan="1">Pacientes hipertensos com s&#x000ed;ndrome metab&#x000f3;lica</td><td align="center" rowspan="1" colspan="1">&#x0003c;130 mmHg</td><td align="center" rowspan="1" colspan="1">144,0</td><td align="center" rowspan="1" colspan="1">92,0</td><td align="center" rowspan="1" colspan="1">1111</td><td align="center" rowspan="1" colspan="1">97</td><td align="center" rowspan="1" colspan="1">55,6</td><td align="center" rowspan="1" colspan="1">43%</td><td align="center" rowspan="1" colspan="1">It&#x000e1;lia</td><td align="center" rowspan="1" colspan="1">27(2)</td></tr><tr><td rowspan="1" colspan="1">#5 Appel</td><td align="center" rowspan="1" colspan="1">2010</td><td align="center" rowspan="1" colspan="1">Pacientes afro-americanos com nefroesclerose hipertensiva</td><td align="center" rowspan="1" colspan="1">&#x0003c;130/80 mmHg</td><td align="center" rowspan="1" colspan="1">142</td><td align="center" rowspan="1" colspan="1">95</td><td align="center" rowspan="1" colspan="1">1094</td><td align="center" rowspan="1" colspan="1">120</td><td align="center" rowspan="1" colspan="1">55,3</td><td align="center" rowspan="1" colspan="1">39%</td><td align="center" rowspan="1" colspan="1">EUA</td><td align="center" rowspan="1" colspan="1">0(0)</td></tr><tr><td rowspan="1" colspan="1">#6 ACCORD</td><td align="center" rowspan="1" colspan="1">2010</td><td align="center" rowspan="1" colspan="1">Pacientes com diabetes tipo 2 e hipertens&#x000e3;o</td><td align="center" rowspan="1" colspan="1">&#x0003c;120 mmHg</td><td align="center" rowspan="1" colspan="1">139,3</td><td align="center" rowspan="1" colspan="1">76,0</td><td align="center" rowspan="1" colspan="1">4733</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">62,2</td><td align="center" rowspan="1" colspan="1">38%</td><td align="center" rowspan="1" colspan="1">EUA</td><td align="center" rowspan="1" colspan="1">232(4,9)</td></tr><tr><td rowspan="1" colspan="1">#7 SPS3</td><td align="center" rowspan="1" colspan="1">2013</td><td align="center" rowspan="1" colspan="1">Pacientes com acidente vascular cerebral lacunar recente</td><td align="center" rowspan="1" colspan="1">&#x0003c;130 mmHg</td><td align="center" rowspan="1" colspan="1">143,4</td><td align="center" rowspan="1" colspan="1">78,2</td><td align="center" rowspan="1" colspan="1">3020</td><td align="center" rowspan="1" colspan="1">377</td><td align="center" rowspan="1" colspan="1">63</td><td align="center" rowspan="1" colspan="1">37%</td><td align="center" rowspan="1" colspan="1">EUA</td><td align="center" rowspan="1" colspan="1">550(18,4)</td></tr><tr><td rowspan="1" colspan="1">#8 SPRINT</td><td align="center" rowspan="1" colspan="1">2015</td><td align="center" rowspan="1" colspan="1">Pacientes hipertensos com risco cardiovascular aumentado</td><td align="center" rowspan="1" colspan="1">&#x0003c;120 mmHg</td><td align="center" rowspan="1" colspan="1">139,7</td><td align="center" rowspan="1" colspan="1">78,1</td><td align="center" rowspan="1" colspan="1">9361</td><td align="center" rowspan="1" colspan="1">562</td><td align="center" rowspan="1" colspan="1">67,9</td><td align="center" rowspan="1" colspan="1">36%</td><td align="center" rowspan="1" colspan="1">EUA</td><td align="center" rowspan="1" colspan="1">986(10,5)</td></tr><tr><td rowspan="1" colspan="1">#9 HOMED-BP</td><td align="center" rowspan="1" colspan="1">2018</td><td align="center" rowspan="1" colspan="1">Pacientes japoneses com hipertens&#x000e3;o, maiores de 40 anos</td><td align="center" rowspan="1" colspan="1">&#x0003c;125/80</td><td align="center" rowspan="1" colspan="1">154</td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">3518</td><td align="center" rowspan="1" colspan="1">51</td><td align="center" rowspan="1" colspan="1">59,6</td><td align="center" rowspan="1" colspan="1">50%</td><td align="center" rowspan="1" colspan="1">Jap&#x000e3;o</td><td align="center" rowspan="1" colspan="1">710(20)</td></tr><tr><td rowspan="1" colspan="1">#10 Zhang</td><td align="center" rowspan="1" colspan="1">2021</td><td align="center" rowspan="1" colspan="1">Pacientes chineses com idade entre 60 e 80 anos com hipertens&#x000e3;o</td><td align="center" rowspan="1" colspan="1">110-130 mmHg</td><td align="center" rowspan="1" colspan="1">146,1</td><td align="center" rowspan="1" colspan="1">86,1</td><td align="center" rowspan="1" colspan="1">8511</td><td align="center" rowspan="1" colspan="1">355</td><td align="center" rowspan="1" colspan="1">66,2</td><td align="center" rowspan="1" colspan="1">54%</td><td align="center" rowspan="1" colspan="1">China</td><td align="center" rowspan="1" colspan="1">234(2,7)</td></tr><tr><td rowspan="1" colspan="1"><bold>Autor principal</bold></td><td align="center" rowspan="1" colspan="1"><bold>Ano de Publica&#x000e7;&#x000e3;o</bold></td><td align="center" rowspan="1" colspan="1"><bold>Desfechos Prim&#x000e1;rios</bold></td><td align="center" rowspan="1" colspan="1"><bold>Eventos CV Grupo Intensivo</bold></td><td align="center" rowspan="1" colspan="1"><bold>Eventos CV Grupo Usual</bold></td><td align="center" rowspan="1" colspan="1"><bold>Morte Grupo Intensivo</bold></td><td align="center" rowspan="1" colspan="1"><bold>Morte Grupo Usual</bold></td><td align="center" rowspan="1" colspan="1"><bold>IAM Grupo Intensivo</bold></td><td align="center" rowspan="1" colspan="1"><bold>IAM Grupo Usual</bold></td><td align="center" rowspan="1" colspan="1"><bold>AVC Grupo Intensivo</bold></td><td align="center" rowspan="1" colspan="1"><bold>AVC Grupo Usual</bold></td><td align="center" rowspan="1" colspan="1"><bold>RoB 2.0</bold></td></tr><tr><td rowspan="1" colspan="1">#02 Schrier</td><td align="center" rowspan="1" colspan="1">2002</td><td align="center" rowspan="1" colspan="1">Altera&#x000e7;&#x000e3;o no clearance de creatinina</td><td align="center" rowspan="1" colspan="1">41/237</td><td align="center" rowspan="1" colspan="1">48/243</td><td align="center" rowspan="1" colspan="1">18/237</td><td align="center" rowspan="1" colspan="1">20/243</td><td align="center" rowspan="1" colspan="1">19/237</td><td align="center" rowspan="1" colspan="1">15/243</td><td align="center" rowspan="1" colspan="1">4/237</td><td align="center" rowspan="1" colspan="1">13/243</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt01" position="float"/>
</td></tr><tr><td rowspan="1" colspan="1">#3 Estacio</td><td align="center" rowspan="1" colspan="1">2006</td><td align="center" rowspan="1" colspan="1">Altera&#x000e7;&#x000e3;o na excre&#x000e7;&#x000e3;o urin&#x000e1;ria de albumina</td><td align="center" rowspan="1" colspan="1">3/66</td><td align="center" rowspan="1" colspan="1">2/63</td><td align="center" rowspan="1" colspan="1">1/66</td><td align="center" rowspan="1" colspan="1">0/63</td><td align="center" rowspan="1" colspan="1">N&#x000e3;o relatado</td><td align="center" rowspan="1" colspan="1">N&#x000e3;o relatado</td><td align="center" rowspan="1" colspan="1">N&#x000e3;o relatado</td><td align="center" rowspan="1" colspan="1">N&#x000e3;o relatado</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt02" position="float"/>
</td></tr><tr><td rowspan="1" colspan="1">#4 CardioSis</td><td align="center" rowspan="1" colspan="1">2009</td><td align="center" rowspan="1" colspan="1">Redu&#x000e7;&#x000e3;o no &#x000ed;ndice de massa ventricular esquerda</td><td align="center" rowspan="1" colspan="1">12/557</td><td align="center" rowspan="1" colspan="1">20/553</td><td align="center" rowspan="1" colspan="1">4/557</td><td align="center" rowspan="1" colspan="1">5/553</td><td align="center" rowspan="1" colspan="1">4/557</td><td align="center" rowspan="1" colspan="1">6/553</td><td align="center" rowspan="1" colspan="1">4/557</td><td align="center" rowspan="1" colspan="1">9/553</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt01" position="float"/>
</td></tr><tr><td rowspan="1" colspan="1">#5 Appel</td><td align="center" rowspan="1" colspan="1">2010</td><td align="center" rowspan="1" colspan="1">Desfecho composto de morte, doen&#x000e7;a renal em est&#x000e1;gio terminal ou redu&#x000e7;&#x000e3;o da taxa de filtra&#x000e7;&#x000e3;o glomerular</td><td align="center" rowspan="1" colspan="1">83/540</td><td align="center" rowspan="1" colspan="1">99/554</td><td align="center" rowspan="1" colspan="1">38/540</td><td align="center" rowspan="1" colspan="1">47/554</td><td align="center" rowspan="1" colspan="1">19/540</td><td align="center" rowspan="1" colspan="1">23/554</td><td align="center" rowspan="1" colspan="1">26/540</td><td align="center" rowspan="1" colspan="1">29/554</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt02" position="float"/>
</td></tr><tr><td rowspan="1" colspan="1">#6 ACCORD</td><td align="center" rowspan="1" colspan="1">2010</td><td align="center" rowspan="1" colspan="1">Desfecho composto de IAM, AVC e morte</td><td align="center" rowspan="1" colspan="1">310/2363</td><td align="center" rowspan="1" colspan="1">345/2371</td><td align="center" rowspan="1" colspan="1">150/2363</td><td align="center" rowspan="1" colspan="1">144/2371</td><td align="center" rowspan="1" colspan="1">126/2363</td><td align="center" rowspan="1" colspan="1">146/2371</td><td align="center" rowspan="1" colspan="1">34/2363</td><td align="center" rowspan="1" colspan="1">55/2371</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt03" position="float"/>
</td></tr><tr><td rowspan="1" colspan="1">#7 SPS3</td><td align="center" rowspan="1" colspan="1">2013</td><td align="center" rowspan="1" colspan="1">AVC recorrente</td><td align="center" rowspan="1" colspan="1">267/1501</td><td align="center" rowspan="1" colspan="1">293/1519</td><td align="center" rowspan="1" colspan="1">106/1501</td><td align="center" rowspan="1" colspan="1">101/1519</td><td align="center" rowspan="1" colspan="1">36/1501</td><td align="center" rowspan="1" colspan="1">40/1519</td><td align="center" rowspan="1" colspan="1">125/1501</td><td align="center" rowspan="1" colspan="1">152/1519</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt02" position="float"/>
</td></tr><tr><td rowspan="1" colspan="1">#8 SPRINT</td><td align="center" rowspan="1" colspan="1">2015</td><td align="center" rowspan="1" colspan="1">Desfecho composto de IAM, AVC, morte cardiovascular, SCA e IC</td><td align="center" rowspan="1" colspan="1">314/4678</td><td align="center" rowspan="1" colspan="1">396/4683</td><td align="center" rowspan="1" colspan="1">155/4678</td><td align="center" rowspan="1" colspan="1">210/4683</td><td align="center" rowspan="1" colspan="1">97/4678</td><td align="center" rowspan="1" colspan="1">116/4683</td><td align="center" rowspan="1" colspan="1">62/4678</td><td align="center" rowspan="1" colspan="1">70/4683</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt03" position="float"/>
</td></tr><tr><td rowspan="1" colspan="1">#9 HOMED-BP</td><td align="center" rowspan="1" colspan="1">2018</td><td align="center" rowspan="1" colspan="1">Desfecho composto de morte cardiovascular, IAM e AVC</td><td align="center" rowspan="1" colspan="1">72/1759</td><td align="center" rowspan="1" colspan="1">75/1759</td><td align="center" rowspan="1" colspan="1">27/1759</td><td align="center" rowspan="1" colspan="1">31/1759</td><td align="center" rowspan="1" colspan="1">25/1759 (***)</td><td align="center" rowspan="1" colspan="1">28/1759 (***)</td><td align="center" rowspan="1" colspan="1">20/1759</td><td align="center" rowspan="1" colspan="1">16/1759</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt01" position="float"/>
</td></tr><tr><td rowspan="1" colspan="1">#10 Zhang</td><td align="center" rowspan="1" colspan="1">2021</td><td align="center" rowspan="1" colspan="1">Desfecho composto de eventos cardiovasculares e morte</td><td align="center" rowspan="1" colspan="1">170/4243</td><td align="center" rowspan="1" colspan="1">217/4268</td><td align="center" rowspan="1" colspan="1">67/4243</td><td align="center" rowspan="1" colspan="1">64/4268</td><td align="center" rowspan="1" colspan="1">55/4243 (**)</td><td align="center" rowspan="1" colspan="1">82/4268 (**)</td><td align="center" rowspan="1" colspan="1">48/4243</td><td align="center" rowspan="1" colspan="1">71/4268</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="0066-782X-abc-122-3-e20240761-gt03" position="float"/>
</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>(**) SCA, n&#x000e3;o IAM isolado; (***) N&#x000e3;o apenas IAM, a doen&#x000e7;a isqu&#x000ea;mica do cora&#x000e7;&#x000e3;o abrangeu morte por angina pectoris, parada cad&#x000ed;aca e infarto do mioc&#x000e1;rdio n&#x000e3;o fatal. AVC: acidente vascular cerebral; CV: cardiovasculares; IAM: infarto agudo do mioc&#x000e1;rdio; IC: insufici&#x000ea;ncia card&#x000ed;aca; PA: press&#x000e3;o arterial; PAD: press&#x000e3;o arterial diast&#x000f3;lica; SCA: s&#x000ed;ndrome coronariana aguda.</p></fn></table-wrap-foot></table-wrap>
</p><p>O efeito para o desfecho composto prim&#x000e1;rio, obtido pela sumariza&#x000e7;&#x000e3;o dos dados dos nove estudos prim&#x000e1;rios, &#x000e9; apresentado na <xref rid="f02" ref-type="fig">Figura 1</xref>. Houve uma redu&#x000e7;&#x000e3;o de 13% nos eventos, favorecendo a estrat&#x000e9;gia de metas mais intensivas de tratamento anti-hipertensivo. Para o mesmo desfecho, quando apenas estudos com baixo risco de vi&#x000e9;s foram inclu&#x000ed;dos (<xref rid="f03" ref-type="fig">Figura 2</xref>), observou-se uma redu&#x000e7;&#x000e3;o de 17% nos eventos, tamb&#x000e9;m favorecendo a estrat&#x000e9;gia de metas mais intensivas de tratamento anti-hipertensivo. A certeza das evid&#x000ea;ncias para essa an&#x000e1;lise foi classificada como alta, de acordo com a metodologia GRADE.</p><p>
<fig position="float" id="f02"><label>Figura 1</label><caption><title>&#x02013; Metan&#x000e1;lise para o desfecho composto prim&#x000e1;rio, definido como infarto do mioc&#x000e1;rdio, acidente vascular cerebral e mortalidade por todas as causas.</title></caption><graphic xlink:href="0066-782X-abc-122-3-e20240761-gf02" position="float"/><attrib>Heterogeneidade: I<sup>2</sup>= 0%, t<sup>2</sup> = 0,0013, p = 0,60</attrib></fig>
</p><p>
<fig position="float" id="f03"><label>Figura 2</label><caption><title>&#x02013; Metan&#x000e1;lise para o desfecho composto prim&#x000e1;rio, definido como infarto do mioc&#x000e1;rdio, acidente vascular cerebral e mortalidade por todas as causas, avaliado apenas para os estudos com baixo risco de vi&#x000e9;s.</title></caption><graphic xlink:href="0066-782X-abc-122-3-e20240761-gf03" position="float"/><attrib>Heterogeneidade: I<sup>2</sup>= 0%, t<sup>2</sup> = 0,0005, p = 0,38</attrib></fig>
</p><p>Quando avaliados separadamente, esses tr&#x000ea;s desfechos mostraram uma redu&#x000e7;&#x000e3;o no infarto do mioc&#x000e1;rdio e no acidente vascular cerebral, favorecendo a estrat&#x000e9;gia de metas mais intensivas, sem diferen&#x000e7;a significativa observada para a mortalidade por todas as causas (Figura 1S).</p><p>O desfecho de progress&#x000e3;o da doen&#x000e7;a renal foi avaliado em quatro estudos inclu&#x000ed;dos, mas apenas dois forneceram dados num&#x000e9;ricos. Devido ao baixo n&#x000fa;mero de estudos e &#x000e0;s diferen&#x000e7;as nas defini&#x000e7;&#x000f5;es de progress&#x000e3;o renal, os autores n&#x000e3;o inclu&#x000ed;ram esse desfecho na avalia&#x000e7;&#x000e3;o prim&#x000e1;ria e n&#x000e3;o realizaram uma metan&#x000e1;lise para esse evento individual.</p><p>Duas revis&#x000f5;es sistem&#x000e1;ticas adicionais avaliadas para leitura completa na primeira busca respondem perguntas PICO com pequenas diferen&#x000e7;as em rela&#x000e7;&#x000e3;o &#x000e0; pergunta cient&#x000ed;fica original desta revis&#x000e3;o. Ambas foram consideradas pelos autores como temas muito relevantes para o sistema de sa&#x000fa;de e subsidiaram duas recomenda&#x000e7;&#x000f5;es cl&#x000ed;nicas adicionais deste documento.<sup><xref rid="B26" ref-type="bibr">26</xref>,<xref rid="B27" ref-type="bibr">27</xref></sup> Os dois documentos foram considerados de boa qualidade t&#x000e9;cnica pelos autores, tendo sido penalizados pela avalia&#x000e7;&#x000e3;o de qualidade AMSTAR 2<sup><xref rid="B28" ref-type="bibr">28</xref></sup> apenas em caracter&#x000ed;sticas que n&#x000e3;o comprometiam a informa&#x000e7;&#x000e3;o central. A avalia&#x000e7;&#x000e3;o de qualidade pela ferramenta AMSTAR 2 destas duas revis&#x000f5;es sistem&#x000e1;ticas adicionais utilizadas para recomenda&#x000e7;&#x000f5;es cl&#x000ed;nicas suplementares est&#x000e3;o na <inline-supplementary-material xlink:href="0066-782X-abc-122-3-e20240761-suppl01.pdf" id="d67e1675" content-type="local-data">Tabela 6S</inline-supplementary-material>.</p><p>A <inline-supplementary-material xlink:href="0066-782X-abc-122-3-e20240761-suppl01.pdf" id="d67e1681" content-type="local-data">Tabela 7S</inline-supplementary-material> descreve o PRISMA deste documento.</p></sec><sec sec-type="discussion"><title>Discuss&#x000e3;o</title><p>A HA &#x000e9; um dos principais fatores de risco modific&#x000e1;vel para morte prematura. Portanto, determinar se metas mais intensivas de redu&#x000e7;&#x000e3;o da PA oferecem benef&#x000ed;cios adicionais para a redu&#x000e7;&#x000e3;o de complica&#x000e7;&#x000f5;es cardiovasculares &#x000e9; de suma import&#x000e2;ncia, alinhando-se &#x000e0; miss&#x000e3;o educativa da SBC. Esta revis&#x000e3;o oferece uma resposta conclusiva para essa lacuna na pr&#x000e1;tica cl&#x000ed;nica.</p><p>Definir o valor-alvo para o tratamento anti-hipertensivo tem sido um desafio na literatura cient&#x000ed;fica devido &#x000e0; variabilidade das metas propostas em diferentes estudos. Embora um ponto de corte de 120/80 mmHg possa ser considerado, ECRs que visaram esse alvo mais rigoroso, frequentemente enfrentaram dificuldades em atingir esses resultados. Por essa raz&#x000e3;o, nesta revis&#x000e3;o sistem&#x000e1;tica, optou-se por incluir estudos nos quais o bra&#x000e7;o de interven&#x000e7;&#x000e3;o visava uma PA abaixo de 130/80 mmHg, objetivo mais alcan&#x000e7;&#x000e1;vel na pr&#x000e1;tica cl&#x000ed;nica real.</p><p>Na busca inicial da literatura, que teve como objetivo identificar revis&#x000f5;es sistem&#x000e1;ticas que abordassem a pergunta PICO predefinida, nenhum documento foi encontrado que pudesse fornecer uma resposta atualizada. Por isso, decidiu-se atualizar o artigo de Sakima et al.<sup><xref rid="B13" ref-type="bibr">13</xref></sup></p><p>Com base nos resultados demonstrados nesta revis&#x000e3;o, que inclui dados de mais de 34.000 indiv&#x000ed;duos, o benef&#x000ed;cio cl&#x000ed;nico de metas mais rigorosas de controle da PA para a popula&#x000e7;&#x000e3;o de pessoas com HA est&#x000e1; bem estabelecido. No entanto, ainda havia incerteza se todos os espectros de risco cardiovascular se beneficiariam desse efeito. Entre os nove estudos inclu&#x000ed;dos, cinco &#x02014; com mais de 6.000 pacientes &#x02014; tinham uma idade m&#x000e9;dia inferior a 60 anos e uma propor&#x000e7;&#x000e3;o significativa de mulheres (40% ou mais). Isso nos permite concluir que uma parte substancial desses participantes estava na categoria de baixo risco de eventos cardiovasculares (risco estimado &#x0003c; 7,5% para 10 anos). Por outro lado, os quatro estudos restantes, que inclu&#x000ed;am pacientes em sua maioria homens com mais de 60 anos, representavam adequadamente o outro extremo de exposi&#x000e7;&#x000e3;o, abrangendo pacientes com alto risco cardiovascular (risco estimado &#x0003e; 15% para 10 anos). Combinando esses dados, podemos supor que estes subgrupos estavam bem representados nos estudos que observaram um benef&#x000ed;cio importante em redu&#x000e7;&#x000e3;o de eventos.</p><p>Outra pergunta relevante que se coloca &#x000e9; se redu&#x000e7;&#x000f5;es adicionais para valores de 120/80 mmHg ou ainda mais baixos, particularmente em pacientes com maior risco cardiovascular e menor probabilidade de efeitos colaterais, poderiam resultar em benef&#x000ed;cios cl&#x000ed;nicos adicionais (e valeria recomendar, se colocados em pr&#x000e1;tica). Com base na metan&#x000e1;lise de dados individuais da <italic toggle="yes">Blood Pressure Lowering Treatment Trialists&#x02019; Collaboration</italic> de 2021, para qualquer faixa inicial de PA (mesmo em indiv&#x000ed;duos com valores sist&#x000f3;licos menores do que 120 mmHg), uma redu&#x000e7;&#x000e3;o de 5 mmHg determina uma redu&#x000e7;&#x000e3;o de 11% nos eventos cardiovasculares.<sup><xref rid="B27" ref-type="bibr">27</xref></sup> Para esses indiv&#x000ed;duos de alto risco, buscar as metas de controle rigoroso propostas pelos estudos SPRINT<sup><xref rid="B8" ref-type="bibr">8</xref></sup> e ACCORD<sup><xref rid="B21" ref-type="bibr">21</xref></sup> pode ser uma op&#x000e7;&#x000e3;o terap&#x000ea;utica vantajosa. Deve-se levar em considera&#x000e7;&#x000e3;o o risco de efeitos colaterais, n&#x000fa;mero de medicamentos utilizados (ades&#x000e3;o) e custos adicionais, contrapondo-se com a significativa redu&#x000e7;&#x000e3;o de eventos cardiovasculares cr&#x000ed;ticos. Esta revis&#x000e3;o sistem&#x000e1;tica serviu de refer&#x000ea;ncia para a recomenda&#x000e7;&#x000e3;o cl&#x000ed;nica de n&#x000fa;mero tr&#x000ea;s neste documento.</p><p>Metas mais rigorosas de controle anti-hipertensivo sempre levantam preocupa&#x000e7;&#x000f5;es sobre eventos adversos, especialmente em pacientes muito idosos ou fr&#x000e1;geis. No entanto, uma metan&#x000e1;lise recente envolvendo 20.895 indiv&#x000ed;duos idosos demonstrou que a estrat&#x000e9;gia de metas intensivas de controle da PA resultou em uma redu&#x000e7;&#x000e3;o de 29% nos principais eventos cardiovasculares, sem evid&#x000ea;ncias de aumento de rea&#x000e7;&#x000f5;es adversas graves ou piora da fun&#x000e7;&#x000e3;o renal.<sup><xref rid="B26" ref-type="bibr">26</xref></sup> Esses achados refor&#x000e7;am ainda mais a ideia de implementar um controle mais rigoroso da HA para a popula&#x000e7;&#x000e3;o em geral, independentemente da idade. No entanto, essa recomenda&#x000e7;&#x000e3;o n&#x000e3;o elimina a necessidade de se considerar as circunst&#x000e2;ncias individuais de cada paciente e de se estabelecer metas menos intensivas para aqueles que s&#x000e3;o fr&#x000e1;geis, t&#x000ea;m expectativa de vida limitada ou possuem caracter&#x000ed;sticas que possam aumentar o risco de efeitos colaterais. Esta revis&#x000e3;o sistem&#x000e1;tica serviu de refer&#x000ea;ncia para a recomenda&#x000e7;&#x000e3;o cl&#x000ed;nica de n&#x000fa;mero dois neste documento.</p><p>Ainda sobre poss&#x000ed;veis eventos adversos do tratamento anti-hipertensivo, existe a discuss&#x000e3;o sobre o fen&#x000f4;meno da curva J. Este se refere &#x000e0; observa&#x000e7;&#x000e3;o de que tanto n&#x000ed;veis excessivamente altos quanto excessivamente baixos de PA est&#x000e3;o associados a um aumento do risco de complica&#x000e7;&#x000f5;es cardiovasculares, formando uma curva em forma de &#x0201c;J&#x0201d; quando plotada em um gr&#x000e1;fico. Esse fen&#x000f4;meno &#x000e9; particularmente observado com a PA diast&#x000f3;lica e sua associa&#x000e7;&#x000e3;o com a doen&#x000e7;a arterial coronariana e outros eventos cardiovasculares. O conceito da rela&#x000e7;&#x000e3;o em curva J entre a PA e desfechos cardiovasculares foi proposto pela primeira vez na d&#x000e9;cada de 1970,<sup><xref rid="B29" ref-type="bibr">29</xref></sup> e posteriormente verificado em v&#x000e1;rios estudos observacionais, como por exemplo o Estudo de Framingham.<sup><xref rid="B30" ref-type="bibr">30</xref></sup> Baseado na mesma revis&#x000e3;o sistem&#x000e1;tica realizada pelo grupo <italic toggle="yes">Blood Pressure Lowering Treatment Trialists&#x02019; Collaboration</italic> de 2021, reunindo 48 ECRs (que possuem uma certeza da evid&#x000ea;ncia mais robusta do que estudos observacionais), quando avaliamos a popula&#x000e7;&#x000e3;o com doen&#x000e7;a cardiovascular pr&#x000e9;via e redu&#x000e7;&#x000f5;es da PA sist&#x000f3;lica al&#x000e9;m de 120 mmHg, n&#x000e3;o foi evidenciado um aumento de eventos cardiovasculares. Ao contr&#x000e1;rio, mesmo nesta popula&#x000e7;&#x000e3;o de muito alto risco e metas muito intensivas de redu&#x000e7;&#x000e3;o da PA, foi observada tamb&#x000e9;m a diminui&#x000e7;&#x000e3;o dos desfechos prim&#x000e1;rios, contradizendo a hip&#x000f3;tese do fen&#x000f4;meno da curva J.</p><p>Uma discuss&#x000e3;o relevante adicional &#x000e9; se o m&#x000e9;todo de medida da PA poderia influenciar os resultados de efeito cl&#x000ed;nico observados. O estudo SPRINT utilizou um m&#x000e9;todo que envolvia a realiza&#x000e7;&#x000e3;o de tr&#x000ea;s aferi&#x000e7;&#x000f5;es de PA durante uma visita ao consult&#x000f3;rio, com o paciente sentado, ap&#x000f3;s um per&#x000ed;odo de cinco minutos de repouso, utilizando um sistema de medida automatizada (Modelo 907, Omron Healthcare), sem a presen&#x000e7;a do m&#x000e9;dico ou outro profissional de sa&#x000fa;de. Este procedimento foi criticado por diferir daqueles utilizados em outros estudos, levantando preocupa&#x000e7;&#x000f5;es sobre a reprodutibilidade de seus resultados. No entanto, um estudo conduzido logo ap&#x000f3;s o SPRINT demonstrou, por meio de entrevistas com os seus participantes, que essa t&#x000e9;cnica foi implementada em menos da metade dos pacientes, sem diferen&#x000e7;as nos desfechos cl&#x000ed;nicos entre os grupos com base no m&#x000e9;todo de mensura&#x000e7;&#x000e3;o da PA.<sup><xref rid="B31" ref-type="bibr">31</xref></sup> Um segundo estudo comparou a t&#x000e9;cnica proposta no ensaio SPRINT com medidas de PA feitas sem repouso pr&#x000e9;vio. Os resultados mostraram uma variabilidade consider&#x000e1;vel na concord&#x000e2;ncia entre os valores, sugerindo que a t&#x000e9;cnica do SPRINT poderia levar a leituras de PA mais baixas.<sup><xref rid="B32" ref-type="bibr">32</xref></sup> No entanto, este foi um estudo observacional, conduzido em um &#x000fa;nico centro, e com um pequeno n&#x000fa;mero de participantes. Essas cr&#x000ed;ticas s&#x000e3;o importantes, mas n&#x000e3;o invalidam os resultados apresentados nesta metan&#x000e1;lise. Destaca-se assim, uma das muitas vantagens a respeito da realiza&#x000e7;&#x000e3;o de uma revis&#x000e3;o sistem&#x000e1;tica, que sumariza os resultados de v&#x000e1;rios estudos, minimizando a influ&#x000ea;ncia de um &#x000fa;nico artigo isolado no resultado final. Ao realizar uma an&#x000e1;lise de sensibilidade excluindo o estudo SPRINT, o benef&#x000ed;cio cl&#x000ed;nico da redu&#x000e7;&#x000e3;o intensiva da PA permanece, mostrando uma redu&#x000e7;&#x000e3;o de 11% nos eventos (Figura 2S).</p><p>Recente revis&#x000e3;o sistem&#x000e1;tica em processo de publica&#x000e7;&#x000e3;o avaliou pergunta PICO semelhante e chegou a resultados parecidos, corroborando as recomenda&#x000e7;&#x000f5;es cl&#x000ed;nicas sugeridas neste documento da SBC.<sup><xref rid="B33" ref-type="bibr">33</xref></sup> Whelton et al.<sup><xref rid="B33" ref-type="bibr">33</xref></sup> observaram para a meta intensiva de controle da PA sist&#x000f3;lica (&#x0003c; 130 mmhg) uma redu&#x000e7;&#x000e3;o de 22% para um desfecho composto de acidente vascular cerebral, doen&#x000e7;a coronariana, insufici&#x000ea;ncia card&#x000ed;aca e morte cardiovascular (<italic toggle="yes">hazard ratio</italic> [HR] = 0,78; intervalo de confian&#x000e7;a [IC] de 95% =0,70 a 0,87; heterogeneidade: I<sup>2</sup> = 64,5%; p = 0,01). Houve diferen&#x000e7;a estat&#x000ed;stica para o desfecho mortalidade geral (HR = 0,89; IC 95% =0,79 a 0,99; heterogeneidade: I<sup>2</sup> = 37%; p = 0,14), embora haja algum grau de imprecis&#x000e3;o para a import&#x000e2;ncia cl&#x000ed;nica deste efeito, comprovado pelo IC.</p><p>Finalmente, um ECR publicado j&#x000e1; na fase final de escrita deste documento tamb&#x000e9;m corrobora os achados desta revis&#x000e3;o sistem&#x000e1;tica.<sup><xref rid="B34" ref-type="bibr">34</xref></sup> Liu et al.<sup><xref rid="B34" ref-type="bibr">34</xref></sup> inclu&#x000ed;ram 11.255 participantes chineses de alto risco cardiovascular (4.359 com diabetes e 3.022 com acidente vascular cerebral pr&#x000e9;vio) que foram designados para tratamento intensivo (n = 5.624) ou tratamento padr&#x000e3;o (n = 5.631). A idade m&#x000e9;dia foi de 64,6 anos. A m&#x000e9;dia da PA sist&#x000f3;lica durante o acompanhamento foi de 119,1 mmHg (desvio padr&#x000e3;o: 11,1) no grupo de tratamento intensivo e 134,8 mmHg (desvio padr&#x000e3;o: 10,5) no grupo de tratamento padr&#x000e3;o. Durante uma mediana de 3,4 anos de acompanhamento, desfechos prim&#x000e1;rios ocorreram em 547 (9,7%) participantes no grupo de tratamento intensivo e 623 (11,1%) no grupo de tratamento padr&#x000e3;o (HR = 0,88; IC 95% = 0,78 a 0,99). Eventos adversos graves de s&#x000ed;ncope foram infrequentes, e ocorreram com maior frequ&#x000ea;ncia no grupo de tratamento intensivo (n = 24 [0,4%] de 5.624) do que no grupo de tratamento padr&#x000e3;o (n = 8 [0,1%] de 5.631; HR = 3,00, IC 95% = 1,35 a 6,68). N&#x000e3;o houve diferen&#x000e7;a significativa entre os grupos nos eventos adversos graves de hipotens&#x000e3;o, anormalidade eletrol&#x000ed;tica, queda prejudicial ou inj&#x000fa;ria renal aguda.</p><p>Outros fatores, al&#x000e9;m de benef&#x000ed;cios e malef&#x000ed;cios cl&#x000ed;nicos, devem ser considerados por um Painel de Recomenda&#x000e7;&#x000f5;es ao tomar a decis&#x000e3;o final para uma recomenda&#x000e7;&#x000e3;o cl&#x000ed;nica, de acordo com a estrutura de Evid&#x000ea;ncias para Decis&#x000e3;o da metodologia GRADE. O custo &#x000e9; um desses fatores. No Brasil, as principais classes de medicamentos anti-hipertensivos s&#x000e3;o fornecidas gratuitamente pelo Minist&#x000e9;rio da Sa&#x000fa;de em todo o pa&#x000ed;s, o que facilita a implementa&#x000e7;&#x000e3;o da estrat&#x000e9;gia intensiva recomendada neste documento.<sup><xref rid="B35" ref-type="bibr">35</xref></sup></p><p>A ades&#x000e3;o dos pacientes aos medicamentos prescritos pode ser um desafio, pois metas mais rigorosas de controle da PA normalmente exigem o uso maior de medicamentos para alcan&#x000e7;ar os resultados desejados. Estrat&#x000e9;gias para melhorar a ades&#x000e3;o, como simplificar os esquemas posol&#x000f3;gicos (prescrevendo medicamentos que requerem um menor n&#x000fa;mero de doses por dia),<sup><xref rid="B36" ref-type="bibr">36</xref></sup> utilizar medicamentos combinados em um &#x000fa;nico comprimido,<sup><xref rid="B37" ref-type="bibr">37</xref></sup> incentivar os pacientes a monitorarem sua PA no domic&#x000ed;lio<sup><xref rid="B38" ref-type="bibr">38</xref></sup> e promover uma rela&#x000e7;&#x000e3;o pr&#x000f3;xima entre os profissionais de sa&#x000fa;de e os pacientes,<sup><xref rid="B39" ref-type="bibr">39</xref></sup> podem contribuir para o sucesso da estrat&#x000e9;gia.</p><p>Outra abordagem para melhorar a ades&#x000e3;o dos pacientes &#x000e9; envolv&#x000ea;-los no processo de tomada de decis&#x000e3;o. Utilizando calculadoras de predi&#x000e7;&#x000e3;o de risco cardiovascular, &#x000e9; poss&#x000ed;vel determinar a probabilidade individual de eventos cardiovasculares nos pr&#x000f3;ximos 10 anos.<sup><xref rid="B40" ref-type="bibr">40</xref></sup> Com base nessa estimativa, os pacientes podem ser esclarecidos sobre o real significado de uma redu&#x000e7;&#x000e3;o adicional na PA e consequentemente no risco cardiovascular futuro, considerando tamb&#x000e9;m as poss&#x000ed;veis desvantagens (eventos adversos, custo, ades&#x000e3;o, etc.). Isso permite uma melhor compreens&#x000e3;o da estrat&#x000e9;gia proposta como um todo, e o efeito da estrat&#x000e9;gia por tempo indeterminado.</p><p>Esta revis&#x000e3;o sistem&#x000e1;tica e metan&#x000e1;lise apresenta algumas limita&#x000e7;&#x000f5;es. Primeiramente, h&#x000e1; uma compreens&#x000ed;vel heterogeneidade entre as caracter&#x000ed;sticas dos diversos estudos sobre o tema. Eles diferem em v&#x000e1;rios aspectos, incluindo as defini&#x000e7;&#x000f5;es das metas de tratamento intensivo anti-hipertensivo, a idade m&#x000e9;dia dos participantes, os m&#x000e9;todos de medida da PA e o risco cardiovascular basal dos pacientes inclu&#x000ed;dos, entre outros. Em segundo lugar, h&#x000e1; informa&#x000e7;&#x000f5;es limitadas nos estudos em rela&#x000e7;&#x000e3;o &#x000e0; progress&#x000e3;o da doen&#x000e7;a renal em pacientes j&#x000e1; acometidos por doen&#x000e7;a renal cr&#x000f4;nica. Embora este tenha sido um desfecho cl&#x000ed;nico predefinido no protocolo, n&#x000e3;o foi amplamente investigado nos estudos inclu&#x000ed;dos, o que impede a formula&#x000e7;&#x000e3;o de conclus&#x000f5;es definitivas. Por &#x000fa;ltimo, o tempo de seguimento dos estudos variou entre dois e cinco anos, aproximadamente. O tempo de tratamento para HA &#x000e9; indefinido, a princ&#x000ed;pio para o total de vida restante do paciente hipertenso. Portanto, o efeito cl&#x000ed;nico comprovado em um n&#x000fa;mero limitado de anos pode estar subdimensionado para uma estrat&#x000e9;gia cl&#x000ed;nica de muito mais longo prazo.</p></sec><sec sec-type="conclusions"><title>Conclus&#x000e3;o</title><p>A HA continua sendo um enorme desafio em sa&#x000fa;de, com profundas implica&#x000e7;&#x000f5;es para a morbidade e mortalidade cardiovascular da popula&#x000e7;&#x000e3;o brasileira. Os achados desta revis&#x000e3;o ressaltam os benef&#x000ed;cios das metas intensivas de tratamento anti-hipertensivo, que demonstraram reduzir significativamente a incid&#x000ea;ncia de eventos cardiovasculares importantes. No entanto, a decis&#x000e3;o de adotar metas mais agressivas de controle da PA deve ser individualizada, levando-se em considera&#x000e7;&#x000e3;o fatores espec&#x000ed;ficos do paciente, como idade, fragilidade e risco de eventos adversos. Al&#x000e9;m disso, garantir a ades&#x000e3;o dos pacientes aos esquemas medicamentosos prescritos &#x000e9; crucial para o sucesso de qualquer estrat&#x000e9;gia de tratamento. Ao considerar os potenciais benef&#x000ed;cios e riscos, envolvendo o paciente na tomada de decis&#x000e3;o final, os profissionais de sa&#x000fa;de podem otimizar o manejo da HA e melhorar os resultados cl&#x000ed;nicos do paciente e do sistema de sa&#x000fa;de.</p></sec></body><back><fn-group><fn fn-type="other"><p><bold>Vincula&#x000e7;&#x000e3;o Acad&#x000ea;mica:</bold> N&#x000e3;o h&#x000e1; vincula&#x000e7;&#x000e3;o deste estudo a programas de p&#x000f3;s-gradua&#x000e7;&#x000e3;o.</p></fn><fn fn-type="other"><p><bold>Aprova&#x000e7;&#x000e3;o &#x000c9;tica e Consentimento Informado:</bold> Este artigo n&#x000e3;o cont&#x000e9;m estudos com humanos ou animais realizados por nenhum dos autores.</p></fn><fn fn-type="supplementary-material" id="fn_ast1"><p><bold>* Material suplementar:</bold> Para informa&#x000e7;&#x000e3;o adicional, por favor, <inline-supplementary-material xlink:href="0066-782X-abc-122-3-e20240761-suppl01.pdf" id="d67e3034" content-type="local-data">clique aqui</inline-supplementary-material>.</p></fn></fn-group><fn-group><fn fn-type="financial-disclosure"><p><bold>Fontes de Financiamento:</bold> O presente estudo n&#x000e3;o teve fontes de financiamento externas.</p></fn></fn-group><ref-list><title>Refer&#x000ea;ncias</title><ref id="B1"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><source>Global Health Observatory Data Repository</source><comment>Internet</comment><publisher-loc>Geneva</publisher-loc><publisher-name>WHO</publisher-name><year>2023</year><date-in-citation content-type="cited-date">cited 2024 Aug 31</date-in-citation><ext-link xlink:href="https://www.who.int/data/gho" ext-link-type="uri">https://www.who.int/data/gho</ext-link></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mills</surname><given-names>KT</given-names></name>
<name><surname>Bundy</surname><given-names>JD</given-names></name>
<name><surname>Kelly</surname><given-names>TN</given-names></name>
<name><surname>Reed</surname><given-names>JE</given-names></name>
<name><surname>Kearney</surname><given-names>PM</given-names></name>
<name><surname>Reynolds</surname><given-names>K</given-names></name>
<etal>et al</etal>
</person-group><article-title>Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies from 90 Countries</article-title><source>Circulation</source><year>2016</year><volume>134</volume><issue>6</issue><fpage>441</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.115.018912</pub-id><pub-id pub-id-type="pmid">27502908</pub-id>
</element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>Brasil</collab>
<collab>Minist&#x000e9;rio da Sa&#x000fa;de</collab>
</person-group><source>Vigitel Brasil 2020: Vigil&#x000e2;ncia de Fatores de Risco e Prote&#x000e7;&#x000e3;o para Doen&#x000e7;as Cr&#x000f4;nicas por Inqu&#x000e9;rito Telef&#x000f4;nico</source><publisher-loc>Bras&#x000ed;lia</publisher-loc><publisher-name>Minist&#x000e9;rio da Sa&#x000fa;de</publisher-name><year>2021</year></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author">
<collab>GBD 2019 Brazil Collaborators</collab>
</person-group><article-title>The Burden of Disease in Brazil, 1990-2019: A Systematic Analysis for the Global Burden of Disease Study 2019</article-title><source>Lancet</source><year>2018</year><volume>392</volume><issue>10149</issue><fpage>760</fpage><lpage>775</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(18)31221-2</pub-id><pub-id pub-id-type="pmid">30037735</pub-id>
</element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Malachias</surname><given-names>MVB</given-names></name>
<name><surname>Gomes</surname><given-names>MAM</given-names></name>
<name><surname>Nobre</surname><given-names>F</given-names></name>
<name><surname>Alessi</surname><given-names>A</given-names></name>
<name><surname>Feitosa</surname><given-names>AD</given-names></name>
<name><surname>Coelho</surname><given-names>EB</given-names></name>
</person-group><article-title>7th Brazilian Guideline of Arterial Hypertension: Chapter 2 - Diagnosis and Classification</article-title><source>Arq Bras Cardiol</source><year>2016</year><volume>107</volume><issue>3</issue><supplement>Suppl 3</supplement><fpage>7</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.5935/abc.20160152</pub-id><pub-id pub-id-type="pmid">27819381</pub-id>
</element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bandeira</surname><given-names>TFGS</given-names></name>
<name><surname>Mosegui</surname><given-names>GBG</given-names></name>
<name><surname>Vianna</surname><given-names>CMM</given-names></name>
<name><surname>L&#x000f3;pez</surname><given-names>AJG</given-names></name>
</person-group><article-title>Estimativa de Produtividade Perdida Atribu&#x000ed;da a Doen&#x000e7;as Cardiovasculares na Am&#x000e9;rica do Sul</article-title><source>Arq Bras Cardiol</source><year>2024</year><volume>121</volume><issue>3</issue><elocation-id>e20230521</elocation-id><pub-id pub-id-type="doi">10.36660/abc.20230521</pub-id><pub-id pub-id-type="pmid">38597555</pub-id>
</element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Whelton</surname><given-names>PK</given-names></name>
<name><surname>Carey</surname><given-names>RM</given-names></name>
<name><surname>Aronow</surname><given-names>WS</given-names></name>
<name><surname>Casey</surname><given-names>DE</given-names></name>
<name><surname>Collins</surname><given-names>KJ</given-names></name>
<name><surname>Himmelfarb</surname><given-names>CD</given-names></name>
<etal>et at</etal>
</person-group><article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines</article-title><source>J Am Coll Cardiol</source><year>2018</year><volume>71</volume><issue>19</issue><fpage>e127</fpage><lpage>e248</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2017.11.006</pub-id><pub-id pub-id-type="pmid">29146535</pub-id>
</element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author">
<collab>SPRINT Research Group</collab>
<name><surname>Wright</surname><given-names>JT</given-names><suffix>Jr</suffix></name>
<name><surname>Williamson</surname><given-names>JD</given-names></name>
<name><surname>Whelton</surname><given-names>PK</given-names></name>
<name><surname>Snyder</surname><given-names>JK</given-names></name>
<name><surname>Sink</surname><given-names>KM</given-names></name>
<etal>et al</etal>
</person-group><article-title>A Randomized Trial of Intensive Versus Standard Blood-Pressure Control</article-title><source>N Engl J Medi</source><year>2015</year><volume>373</volume><issue>22</issue><fpage>2103</fpage><lpage>2116</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1511939</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Williamson</surname><given-names>JD</given-names></name>
<name><surname>Supiano</surname><given-names>MA</given-names></name>
<name><surname>Applegate</surname><given-names>WB</given-names></name>
<name><surname>Berlowitz</surname><given-names>DR</given-names></name>
<name><surname>Campbell</surname><given-names>RC</given-names></name>
<name><surname>Chertow</surname><given-names>GM</given-names></name>
<etal>et al</etal>
</person-group><article-title>Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged= 75 years: A Randomized Clinical Trial</article-title><source>JAMA</source><year>2016</year><volume>315</volume><issue>24</issue><fpage>2673</fpage><lpage>2682</lpage><pub-id pub-id-type="doi">10.1001/jama.2016.7050</pub-id><pub-id pub-id-type="pmid">27195814</pub-id>
</element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="book"><person-group person-group-type="editor">
<name><surname>Tricco</surname><given-names>AC</given-names></name>
<name><surname>Langlois</surname><given-names>EV</given-names></name>
<name><surname>Straus</surname><given-names>SE</given-names></name>
<role>editors</role>
</person-group><source>Rapid Reviews to Strengthen Health Policy and Systems: A Practical Guide</source><publisher-loc>Geneva</publisher-loc><publisher-name>WHO</publisher-name><year>2017</year></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garritty</surname><given-names>C</given-names></name>
<name><surname>Gartehner</surname><given-names>G</given-names></name>
<name><surname>Nussbaumer-Streit</surname><given-names>B</given-names></name>
<name><surname>King</surname><given-names>VJ</given-names></name>
<name><surname>Hamel</surname><given-names>C</given-names></name>
<name><surname>Affengruber</surname><given-names>L</given-names></name>
<etal>et al</etal>
</person-group><article-title>Cochrane Rapid Reviews Methods Group Offers Evidence-Informed Guidance to Conduct Rapid Reviews</article-title><source>J Clin Epidemiol</source><year>2021</year><volume>130</volume><fpage>13</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.jclinepi.2020.10.007</pub-id><pub-id pub-id-type="pmid">33068715</pub-id>
</element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Dobbins</surname><given-names>M</given-names></name>
</person-group><source>Rapid Review Guidebook: Steps for Conducting a Rapid Review</source><publisher-loc>Hamilton</publisher-loc><publisher-name>McMaster</publisher-name><year>2017</year></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sakima</surname><given-names>A</given-names></name>
<name><surname>Satonaka</surname><given-names>H</given-names></name>
<name><surname>Nishida</surname><given-names>N</given-names></name>
<name><surname>Yatsu</surname><given-names>K</given-names></name>
<name><surname>Arima</surname><given-names>H</given-names></name>
</person-group><article-title>Optimal Blood Pressure Targets for Patients with Hypertension: A Systematic Review and Meta-Analysis</article-title><source>Hypertens Res</source><year>2019</year><volume>42</volume><issue>4</issue><fpage>483</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1038/s41440-018-0123-4</pub-id><pub-id pub-id-type="pmid">30948822</pub-id>
</element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>Cochrane Collaboration</collab>
</person-group><source>RoB 2: A Revised Tool for Assessing Risk of Bias in Randomized Trials</source><comment>Internet</comment><publisher-loc>London</publisher-loc><publisher-name>Cochrane Collaboration</publisher-name><year>2019</year><date-in-citation content-type="cited-date">cited 2024 Aug 31</date-in-citation><ext-link xlink:href="https://methods.cochrane.org/bias/resources/rob-2-revised-cochrane-risk-bias-tool-randomized-trials" ext-link-type="uri">https://methods.cochrane.org/bias/resources/rob-2-revised-cochrane-risk-bias-tool-randomized-trials</ext-link></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="book"><person-group person-group-type="editor">
<name><surname>Sch&#x000fc;nemann</surname><given-names>H</given-names></name>
<name><surname>Brozek</surname><given-names>J</given-names></name>
<name><surname>Guyatt</surname><given-names>G</given-names></name>
<name><surname>Oxman</surname><given-names>A</given-names></name>
<role>editors</role>
</person-group><source>GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations</source><publisher-loc>Hamilton</publisher-loc><publisher-name>The GRADE Working Group</publisher-name><year>2013</year><date-in-citation content-type="cited-date">cited 2024 Aug 31</date-in-citation><ext-link xlink:href="https://gdt.gradepro.org/app/handbook/handbook.html" ext-link-type="uri">https://gdt.gradepro.org/app/handbook/handbook.html</ext-link></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hannson</surname><given-names>L</given-names></name>
</person-group><article-title>The BBB Study: The Effect of Intensified Antihypertensive Treatment on the Level of Blood Pressure, Side-Effects, Morbidity and Mortality in "Well-Treated" Hypertensive Patients</article-title><source>Behandla Blodtryck B&#x000e4;ttre. Blood Press</source><year>1994</year><volume>3</volume><issue>4</issue><fpage>248</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.3109/08037059409102265</pub-id><pub-id pub-id-type="pmid">7994450</pub-id>
</element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schrier</surname><given-names>RW</given-names></name>
<name><surname>Estacio</surname><given-names>RO</given-names></name>
<name><surname>Esler</surname><given-names>A</given-names></name>
<name><surname>Mehler</surname><given-names>P</given-names></name>
</person-group><article-title>Effects of Aggressive Blood Pressure Control in Normotensive Type 2 Diabetic Patients on Albuminuria, Retinopathy and Strokes</article-title><source>Kidney Int</source><year>2002</year><volume>61</volume><issue>3</issue><fpage>1086</fpage><lpage>1097</lpage><pub-id pub-id-type="doi">10.1046/j.1523-1755.2002.00213.x</pub-id><pub-id pub-id-type="pmid">11849464</pub-id>
</element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Estacio</surname><given-names>RO</given-names></name>
<name><surname>Coll</surname><given-names>JR</given-names></name>
<name><surname>Tran</surname><given-names>ZV</given-names></name>
<name><surname>Schrier</surname><given-names>RW</given-names></name>
</person-group><article-title>Effect of Intensive Blood Pressure Control with Valsartan on Urinary Albumin Excretion in Normotensive Patients with Type 2 Diabetes</article-title><source>Am J Hypertens</source><year>2006</year><volume>19</volume><issue>12</issue><fpage>1241</fpage><lpage>1248</lpage><pub-id pub-id-type="doi">10.1016/j.amjhyper.2006.05.011</pub-id><pub-id pub-id-type="pmid">17161769</pub-id>
</element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Verdecchia</surname><given-names>P</given-names></name>
<name><surname>Staessen</surname><given-names>JA</given-names></name>
<name><surname>Angeli</surname><given-names>F</given-names></name>
<name><surname>Simone</surname><given-names>G</given-names></name>
<name><surname>Achilli</surname><given-names>A</given-names></name>
<name><surname>Ganau</surname><given-names>A</given-names></name>
<etal>et al</etal>
</person-group><article-title>Usual versus Tight Control of Systolic Blood Pressure in Non-Diabetic Patients with Hypertension (Cardio-Sis): An Open-Label Randomised Trial</article-title><source>Lancet</source><year>2009</year><volume>374</volume><issue>9689</issue><fpage>525</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(09)61340-4</pub-id><pub-id pub-id-type="pmid">19683638</pub-id>
</element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Appel</surname><given-names>LJ</given-names></name>
<name><surname>Wright</surname><given-names>JT</given-names><suffix>Jr</suffix></name>
<name><surname>Greene</surname><given-names>T</given-names></name>
<name><surname>Agodoa</surname><given-names>LY</given-names></name>
<name><surname>Astor</surname><given-names>BC</given-names></name>
<name><surname>Bakris</surname><given-names>GL</given-names></name>
<etal>et al</etal>
</person-group><article-title>Intensive Blood-Pressure Control in Hypertensive Chronic Kidney Disease</article-title><source>N Engl J Med</source><year>2010</year><volume>363</volume><issue>10</issue><fpage>918</fpage><lpage>929</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0910975</pub-id><pub-id pub-id-type="pmid">20818902</pub-id>
</element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author">
<collab>ACCORD Study Group</collab>
<name><surname>Cushman</surname><given-names>WC</given-names></name>
<name><surname>Evans</surname><given-names>GW</given-names></name>
<name><surname>Byington</surname><given-names>RP</given-names></name>
<name><surname>Goff</surname><given-names>DC</given-names><suffix>Jr</suffix></name>
<name><surname>Grimm</surname><given-names>RH</given-names><suffix>Jr</suffix></name>
<etal>et al</etal>
</person-group><article-title>Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus</article-title><source>N Engl J Med</source><year>2010</year><volume>362</volume><issue>17</issue><fpage>1575</fpage><lpage>1585</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1001286</pub-id><pub-id pub-id-type="pmid">20228401</pub-id>
</element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author">
<collab>SPS3 Study Group</collab>
<name><surname>Benavente</surname><given-names>OR</given-names></name>
<name><surname>Coffey</surname><given-names>CS</given-names></name>
<name><surname>Conwit</surname><given-names>R</given-names></name>
<name><surname>Hart</surname><given-names>RG</given-names></name>
<name><surname>McClure</surname><given-names>LA</given-names></name>
<etal>et al</etal>
</person-group><article-title>Blood-Pressure Targets in Patients with Recent Lacunar Stroke: The SPS3 Randomised Trial</article-title><source>Lancet</source><year>2013</year><volume>382</volume><issue>9891</issue><fpage>507</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(13)60852-1</pub-id><pub-id pub-id-type="pmid">23726159</pub-id>
</element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Asayama</surname><given-names>K</given-names></name>
<name><surname>Ohkubo</surname><given-names>T</given-names></name>
<name><surname>Metoki</surname><given-names>H</given-names></name>
<name><surname>Obara</surname><given-names>T</given-names></name>
<name><surname>Inoue</surname><given-names>R</given-names></name>
<name><surname>Kikuya</surname><given-names>M</given-names></name>
<etal>et al</etal>
</person-group><article-title>Cardiovascular Outcomes in the First Trial of Antihypertensive Therapy Guided by Self-Measured Home Blood Pressure</article-title><source>Hypertens Res</source><year>2012</year><volume>35</volume><issue>11</issue><fpage>1102</fpage><lpage>1110</lpage><pub-id pub-id-type="doi">10.1038/hr.2012.125</pub-id><pub-id pub-id-type="pmid">22895063</pub-id>
</element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>W</given-names></name>
<name><surname>Zhang</surname><given-names>S</given-names></name>
<name><surname>Deng</surname><given-names>Y</given-names></name>
<name><surname>Wu</surname><given-names>S</given-names></name>
<name><surname>Ren</surname><given-names>J</given-names></name>
<name><surname>Sun</surname><given-names>G</given-names></name>
<etal>et al</etal>
</person-group><article-title>Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension</article-title><source>N Engl J Med</source><year>2021</year><volume>385</volume><issue>14</issue><fpage>1268</fpage><lpage>1279</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2111437</pub-id><pub-id pub-id-type="pmid">34491661</pub-id>
</element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author">
<collab>SPRINT Research Group</collab>
<name><surname>Lewis</surname><given-names>CE</given-names></name>
<name><surname>Fine</surname><given-names>LJ</given-names></name>
<name><surname>Beddhu</surname><given-names>S</given-names></name>
<name><surname>Cheung</surname><given-names>AK</given-names></name>
<name><surname>Cushman</surname><given-names>WC</given-names></name>
<etal>et al</etal>
</person-group><article-title>Final Report of a Trial of Intensive versus Standard Blood-Pressure Control</article-title><source>N Engl J Med</source><year>2021</year><volume>384</volume><issue>20</issue><fpage>1921</fpage><lpage>1930</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1901281</pub-id><pub-id pub-id-type="pmid">34010531</pub-id>
</element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Seidu</surname><given-names>S</given-names></name>
<name><surname>Willis</surname><given-names>H</given-names></name>
<name><surname>Kunutsor</surname><given-names>SK</given-names></name>
<name><surname>Khunti</surname><given-names>K</given-names></name>
</person-group><article-title>Intensive versus Standard Blood Pressure Control in Older Persons with or Without Diabetes: A Systematic Review and Meta-Analysis of Randomised Controlled Trials</article-title><source>J R Soc Med</source><year>2023</year><volume>116</volume><issue>4</issue><fpage>133</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1177/01410768231156997</pub-id><pub-id pub-id-type="pmid">36825537</pub-id>
</element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author">
<collab>Blood Pressure Lowering Treatment Trialists' Collaboration</collab>
</person-group><article-title>Pharmacological Blood Pressure Lowering for Primary and Secondary Prevention of Cardiovascular Disease Across Different Levels of Blood Pressure: An Individual Participant-Level Data Meta-Analysis</article-title><source>Lancet</source><year>2021</year><volume>397</volume><issue>10285</issue><fpage>1625</fpage><lpage>1636</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)00590-0</pub-id><pub-id pub-id-type="pmid">33933205</pub-id>
</element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shea</surname><given-names>BJ</given-names></name>
<name><surname>Reeves</surname><given-names>BC</given-names></name>
<name><surname>Wells</surname><given-names>G</given-names></name>
<name><surname>Thuku</surname><given-names>M</given-names></name>
<name><surname>Hamel</surname><given-names>C</given-names></name>
<name><surname>Moran</surname><given-names>J</given-names></name>
<etal>et al</etal>
</person-group><article-title>AMSTAR 2: A Critical Appraisal Tool for Systematic Reviews that Include Randomised or Non-Randomised Studies of Healthcare Interventions, or Both</article-title><source>BMJ</source><year>2017</year><volume>358</volume><fpage>j4008</fpage><pub-id pub-id-type="doi">10.1136/bmj.j4008</pub-id><pub-id pub-id-type="pmid">28935701</pub-id>
</element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stewart</surname><given-names>IM</given-names></name>
</person-group><article-title>Long-Term Observations on High Blood-Pressure Presenting in Fit Young Men</article-title><source>Lancet</source><year>1971</year><volume>1</volume><issue>7695</issue><fpage>355</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(71)92205-7</pub-id><pub-id pub-id-type="pmid">4100208</pub-id>
</element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>D'Agostino</surname><given-names>RB</given-names></name>
<name><surname>Belanger</surname><given-names>AJ</given-names></name>
<name><surname>Kannel</surname><given-names>WB</given-names></name>
<name><surname>Cruickshank</surname><given-names>JM</given-names></name>
</person-group><article-title>Relation of Low Diastolic Blood Pressure to Coronary Heart Disease Death in Presence of Myocardial Infarction: The Framingham Study</article-title><source>BMJ</source><year>1991</year><volume>303</volume><issue>6799</issue><fpage>385</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1136/bmj.303.6799.385</pub-id><pub-id pub-id-type="pmid">1912805</pub-id>
</element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Johnson</surname><given-names>KC</given-names></name>
<name><surname>Whelton</surname><given-names>PK</given-names></name>
<name><surname>Cushman</surname><given-names>WC</given-names></name>
<name><surname>Cutler</surname><given-names>JA</given-names></name>
<name><surname>Evans</surname><given-names>GW</given-names></name>
<name><surname>Snyder</surname><given-names>JK</given-names></name>
<etal>et al</etal>
</person-group><article-title>Blood Pressure Measurement in SPRINT (Systolic Blood Pressure Intervention Trial)</article-title><source>Hypertension</source><year>2018</year><volume>71</volume><issue>5</issue><fpage>848</fpage><lpage>857</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.117.10479</pub-id><pub-id pub-id-type="pmid">29531173</pub-id>
</element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Agarwal</surname><given-names>R</given-names></name>
</person-group><article-title>Implications of Blood Pressure Measurement Technique for Implementation of Systolic Blood Pressure Intervention Trial (SPRINT)</article-title><source>J Am Heart Assoc</source><year>2017</year><volume>6</volume><issue>2</issue><elocation-id>e004536</elocation-id><pub-id pub-id-type="doi">10.1161/JAHA.116.004536</pub-id><pub-id pub-id-type="pmid">28159816</pub-id>
</element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Whelton</surname><given-names>PK</given-names></name>
<name><surname>O'Connell</surname><given-names>S</given-names></name>
<name><surname>Mills</surname><given-names>KT</given-names></name>
<name><surname>He</surname><given-names>J</given-names></name>
</person-group><article-title>Optimal Antihypertensive Systolic Blood Pressure: A Systematic Review and Meta-Analysis</article-title><source>Hypertension</source><year>2024</year><volume>81</volume><issue>11</issue><fpage>2329</fpage><lpage>2339</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.124.23597</pub-id><pub-id pub-id-type="pmid">39263736</pub-id>
</element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>J</given-names></name>
<name><surname>Zhang</surname><given-names>X</given-names></name>
<name><surname>Wang</surname><given-names>Y</given-names></name>
<name><surname>Chen</surname><given-names>G</given-names></name>
<name><surname>Li</surname><given-names>H</given-names></name>
<name><surname>Huang</surname><given-names>J</given-names></name>
<etal>et al</etal>
</person-group><article-title>Lowering Systolic Blood Pressure to Less Than 120 mm Hg versus Less than 140 mm Hg in Patients with High Cardiovascular Risk with and Without Diabetes or Previous Stroke: An Open-Label, Blinded-Outcome, Randomised Trial</article-title><source>Lancet</source><year>2024</year><volume>404</volume><issue>10449</issue><fpage>245</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(24)01028-6</pub-id><pub-id pub-id-type="pmid">38945140</pub-id>
</element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>Brasil</collab>
<collab>Minist&#x000e9;rio da Sa&#x000fa;de</collab>
</person-group><source>Programa Farm&#x000e1;cia Popular do Brasil: Acesso aos Medicamentos</source><comment>Internet</comment><publisher-loc>Bras&#x000ed;lia</publisher-loc><publisher-name>Minist&#x000e9;rio da Sa&#x000fa;de</publisher-name><year>2024</year><date-in-citation content-type="cited-date">cited 2024 Aug 31</date-in-citation><ext-link xlink:href="http://www.saude.gov.br/farmaciapopular" ext-link-type="uri">http://www.saude.gov.br/farmaciapopular</ext-link></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Claxton</surname><given-names>AJ</given-names></name>
<name><surname>Cramer</surname><given-names>J</given-names></name>
<name><surname>Pierce</surname><given-names>C</given-names></name>
</person-group><article-title>A Systematic Review of the Associations between Dose Regimens and Medication Compliance</article-title><source>Clin Ther</source><year>2001</year><volume>23</volume><issue>8</issue><fpage>1296</fpage><lpage>1310</lpage><pub-id pub-id-type="doi">10.1016/s0149-2918(01)80109-0</pub-id><pub-id pub-id-type="pmid">11558866</pub-id>
</element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>AK</given-names></name>
<name><surname>Arshad</surname><given-names>S</given-names></name>
<name><surname>Poulter</surname><given-names>NR</given-names></name>
</person-group><article-title>Compliance, Safety, and Effectiveness of Fixed-Dose Combinations of Antihypertensive Agents: A Meta-Analysis</article-title><source>Hypertension</source><year>2010</year><volume>55</volume><issue>2</issue><fpage>399</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.109.139816</pub-id><pub-id pub-id-type="pmid">20026768</pub-id>
</element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fletcher</surname><given-names>BR</given-names></name>
<name><surname>Hinton</surname><given-names>L</given-names></name>
<name><surname>Hartmann-Boyce</surname><given-names>J</given-names></name>
<name><surname>Roberts</surname><given-names>NW</given-names></name>
<name><surname>Bobrovitz</surname><given-names>N</given-names></name>
<name><surname>McManus</surname><given-names>RJ</given-names></name>
</person-group><article-title>Self-Monitoring Blood Pressure in Hypertension, Patient and Provider Perspectives: A Systematic Review and Thematic Synthesis</article-title><source>Patient Educ Couns</source><year>2016</year><volume>99</volume><issue>2</issue><fpage>210</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1016/j.pec.2015.08.026</pub-id><pub-id pub-id-type="pmid">26341941</pub-id>
</element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Haynes</surname><given-names>RB</given-names></name>
<name><surname>Ackloo</surname><given-names>E</given-names></name>
<name><surname>Sahota</surname><given-names>N</given-names></name>
<name><surname>McDonald</surname><given-names>HP</given-names></name>
<name><surname>Yao</surname><given-names>X</given-names></name>
</person-group><article-title>Interventions for Enhancing Medication Adherence</article-title><source>Cochrane Database Syst Rev</source><year>2008</year><issue>2</issue><size units="pages">CD000011</size><pub-id pub-id-type="doi">10.1002/14651858.CD000011.pub3</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>National Institute for Health and Care Excellence</collab>
</person-group><source>Cardiovascular Disease: Risk Assessment and Reduction, Including Lipid Modification</source><comment>Internet</comment><publisher-loc>London</publisher-loc><publisher-name>NICE</publisher-name><year>2014</year><date-in-citation content-type="cited-date">cited 2024 Aug 31</date-in-citation><ext-link xlink:href="https://www.nice.org.uk/guidance/ng238/evidence/a-cvd-risk-assessment-tools-primary-prevention-pdf-13253901661" ext-link-type="uri">https://www.nice.org.uk/guidance/ng238/evidence/a-cvd-risk-assessment-tools-primary-prevention-pdf-13253901661</ext-link></element-citation></ref></ref-list></back><sub-article article-type="translation" id="TRen" xml:lang="en"><front-stub><article-id pub-id-type="doi">10.36660/abc.20240761i</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Systematic Review of the Effectiveness of Intensive Antihypertensive Treatment Goals: Brazilian Society of Cardiology (SBC) Recommendation</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7040-396X</contrib-id><name><surname>Brand&#x000e3;o</surname><given-names>Andr&#x000e9;a Araujo</given-names></name><role>Conception and design of the research</role><role>Acquisition of data</role><role>Analysis and interpretation of the data</role><role>Writing of the manuscript</role><role>Critical revision of the manuscript for content</role><xref rid="aff1001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9490-7997</contrib-id><name><surname>Rodrigues</surname><given-names>Cibele Isaac Saad</given-names></name><role>Conception and design of the research</role><role>Acquisition of data</role><role>Analysis and interpretation of the data</role><role>Writing of the manuscript</role><role>Critical revision of the manuscript for content</role><xref rid="aff2001" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4865-6442</contrib-id><name><surname>Bortolotto</surname><given-names>Luiz Aparecido</given-names></name><role>Conception and design of the research</role><role>Acquisition of data</role><role>Analysis and interpretation of the data</role><role>Writing of the manuscript</role><role>Critical revision of the manuscript for content</role><xref rid="aff3001" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9901-6421</contrib-id><name><surname>Luna</surname><given-names>Leonardo Castro</given-names></name><role>Conception and design of the research</role><role>Acquisition of data</role><role>Analysis and interpretation of the data</role><role>Writing of the manuscript</role><role>Critical revision of the manuscript for content</role><role>Statistical analysis</role><xref rid="aff4001" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9487-6139</contrib-id><name><surname>Barros</surname><given-names>Bruno Monteiro</given-names></name><role>Conception and design of the research</role><role>Acquisition of data</role><role>Analysis and interpretation of the data</role><role>Writing of the manuscript</role><role>Critical revision of the manuscript for content</role><xref rid="aff4001" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0797-572X</contrib-id><name><surname>Neves</surname><given-names>Mario Fritsch Toros</given-names></name><role>Conception and design of the research</role><role>Acquisition of data</role><role>Analysis and interpretation of the data</role><role>Writing of the manuscript</role><role>Critical revision of the manuscript for content</role><xref rid="aff1001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7368-4704</contrib-id><name><surname>Moura</surname><given-names>Ana Fl&#x000e1;via de Souza</given-names></name><role>Conception and design of the research</role><role>Acquisition of data</role><role>Analysis and interpretation of the data</role><role>Writing of the manuscript</role><role>Critical revision of the manuscript for content</role><xref rid="aff5001" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3655-4761</contrib-id><name><surname>Plavnik</surname><given-names>Frida Liane</given-names></name><role>Conception and design of the research</role><role>Acquisition of data</role><role>Analysis and interpretation of the data</role><role>Writing of the manuscript</role><role>Critical revision of the manuscript for content</role><xref rid="aff6001" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2081-6846</contrib-id><name><surname>Drager</surname><given-names>Luciano Ferreira</given-names></name><role>Conception and design of the research</role><role>Acquisition of data</role><role>Analysis and interpretation of the data</role><role>Writing of the manuscript</role><role>Critical revision of the manuscript for content</role><xref rid="aff3001" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Moreira</surname><given-names>Osni</given-names><suffix>Filho</suffix></name><role>Conception and design of the research</role><role>Acquisition of data</role><role>Analysis and interpretation of the data</role><role>Writing of the manuscript</role><role>Critical revision of the manuscript for content</role><xref rid="aff7001" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1265-1930</contrib-id><name><surname>Souza</surname><given-names>Weimar Kunz Sebba Barroso de</given-names></name><role>Conception and design of the research</role><role>Acquisition of data</role><role>Analysis and interpretation of the data</role><role>Writing of the manuscript</role><role>Critical revision of the manuscript for content</role><xref rid="aff8001" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Nadruz</surname><given-names>Wilson</given-names></name><role>Conception and design of the research</role><role>Acquisition of data</role><role>Analysis and interpretation of the data</role><role>Writing of the manuscript</role><role>Critical revision of the manuscript for content</role><xref rid="aff9001" ref-type="aff">
<sup>9</sup>
</xref></contrib></contrib-group><aff id="aff1001">
<label>1</label>
<country country="BR">Brazil</country>
<institution content-type="original">Faculdade de Ci&#x000ea;ncias M&#x000e9;dicas &#x02013; Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ &#x02013; Brazil</institution>
</aff><aff id="aff2001">
<label>2</label>
<country country="BR">Brazil</country>
<institution content-type="original">Pontif&#x000ed;cia Universidade Cat&#x000f3;lica de S&#x000e3;o Paulo, Sorocaba, SP &#x02013; Brazil</institution>
</aff><aff id="aff3001">
<label>3</label>
<country country="BR">Brazil</country>
<institution content-type="original">Instituto do Cora&#x000e7;&#x000e3;o do Hospital das Cl&#x000ed;nicas da Faculdade de Medicina da Universidade de S&#x000e3;o Paulo, S&#x000e3;o Paulo, SP &#x02013; Brazil</institution>
</aff><aff id="aff4001">
<label>4</label>
<country country="BR">Brazil</country>
<institution content-type="original">Instituto Nacional de Cardiologia, Rio de Janeiro, RJ &#x02013; Brazil</institution>
</aff><aff id="aff5001">
<label>5</label>
<country country="BR">Brazil</country>
<institution content-type="original">Escola Bahiana de Medicina e Sa&#x000fa;de P&#x000fa;blica, Salvador, BA &#x02013; Brazil</institution>
</aff><aff id="aff6001">
<label>6</label>
<country country="BR">Brazil</country>
<institution content-type="original">Hospital Alem&#x000e3;o Oswaldo Cruz, S&#x000e3;o Paulo, SP &#x02013; Brazil</institution>
</aff><aff id="aff7001">
<label>7</label>
<country country="BR">Brazil</country>
<institution content-type="original">Cl&#x000ed;nica Gapski Moreira, Curitiba, PR &#x02013; Brazil</institution>
</aff><aff id="aff8001">
<label>8</label>
<country country="BR">Brazil</country>
<institution content-type="original">Universidade Federal de Goi&#x000e1;s, Goi&#x000e2;nia, GO &#x02013; Brazil</institution>
</aff><aff id="aff9001">
<label>9</label>
<country country="BR">Brasil</country>
<institution content-type="original">Faculdade de Ci&#x000ea;ncias M&#x000e9;dicas, Universidade Estadual de Campinas (UNICAMP), Campinas, SP &#x02013; Brazil</institution>
</aff><author-notes><corresp id="c01001">
<label>Mailing Address</label>: Andr&#x000e9;a Araujo Brand&#x000e3;o &#x02022; Universidade do Estado do Rio de Janeiro &#x02013; Av. 28 de Setembro, 77. Postal Code 20551-030, Vila Isabel, Rio de Janeiro, RJ &#x02013; Brazil E-mail: andreaaraujobrandao@gmail.com </corresp><fn fn-type="edited-by"><p><bold>Editor responsible for the review:</bold> Paulo B. Veiga Jardim</p></fn><fn fn-type="COI-statement"><p><bold>Potential conflict of interest:</bold> No potential conflict of interest relevant to this article was reported.</p></fn></author-notes><abstract><title>Abstract</title><sec><title>Background</title><p> Strict blood pressure control has been investigated as a strategy to reduce severe cardiovascular events in patients with hypertension. However, there are still doubts about the impact of intensive antihypertensive treatment goals (&#x0003c; 130/80 mmHg) compared to conventional goals (&#x02265; 130/80 mmHg) in preventing myocardial infarction, stroke, mortality, and possible treatment-related adverse effects.</p></sec><sec><title>Objective</title><p> To evaluate the effectiveness of intensive antihypertensive treatment goals in reducing critical cardiovascular events compared to usual goals.</p></sec><sec><title>Methods</title><p> This systematic review included randomized controlled trials (RCTs) that compared intensive blood pressure control goals with conventional goals in adults aged 18 years or older. Studies with at least one of the following outcomes were included: mortality, myocardial infarction, stroke, progression to stage 4 or 5 chronic kidney disease, need for dialysis, or kidney transplantation. Medline, Embase, and Cochrane Library databases were searched up to May 2024. Risk of bias assessment was performed by two independent reviewers using the Cochrane Collaboration&#x02019;s Risk of Bias 2 (RoB 2) tool. Synthesis of results was conducted through meta-analysis for the composite outcome of myocardial infarction, stroke, and all-cause mortality. The certainty of scientific evidence and strength of recommendation followed the methods proposed by the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) tool.</p></sec><sec><title>Results</title><p> Nine RCTs with more than 34,000 participants were included. Intensive treatment was associated with a 13% reduction in cardiovascular events. In the studies with low risk of bias, the reduction was 17%, with high certainty of evidence. Separately, a significant reduction was observed in the outcomes of myocardial infarction and stroke, but not in all-cause mortality. Limited data were found on the progression of kidney disease and the need for dialysis or kidney transplantation.</p></sec><sec><title>Conclusion</title><p> High-quality evidence suggests that more intensive antihypertensive treatment goals significantly reduce cardiovascular events. However, the choice of treatment goals should be individualized, considering factors such as age, frailty, individual cardiovascular risk, and the possibility of adverse events. Adherence to treatment is essential to therapeutic success.</p></sec></abstract><abstract abstract-type="graphical"><p>
<fig position="float" id="f01001"><label>Central Illustration</label><caption><title>: Systematic Review of the Effectiveness of Intensive Antihypertensive Treatment Goals: Brazilian Society of Cardiology (SBC) Recommendation</title></caption><graphic xlink:href="0066-782X-abc-122-3-e20240761-gf01-en" position="float"/><attrib>Heterogeneity: I<sup>2</sup>= 0%; t<sup>2</sup> = 0.0013; p = 0.60</attrib></fig>
</p></abstract><kwd-group><kwd>Hypertension</kwd><kwd>Systematic Review</kwd><kwd>Meta-Analysis</kwd><kwd>Drug Therapy</kwd></kwd-group></front-stub><body><p><bold>Recommendation 1:</bold> The Brazilian Society of Cardiology recommends the strategy of more intensive antihypertensive treatment goals (values below 130/80 mmHg) for adult patients with hypertension, with the aim of reducing major cardiovascular events (myocardial infarction, stroke, and death). This is a strong recommendation with high certainty of evidence.</p><p><bold>Recommendation 2:</bold> The Brazilian Society of Cardiology recommends the strategy of more intensive antihypertensive treatment goals (values below 130/80 mmHg) for elderly patients with hypertension (age &#x0003e; 65 years), with the aim of reducing future major cardiovascular events (myocardial infarction, stroke, and death). This is a strong recommendation with high certainty of evidence. This recommendation should be assessed on an individual basis when treating frail elderly patients or patients with limited life expectancy.</p><p><bold>Recommendation 3:</bold> The Brazilian Society of Cardiology recommends the strategy of more intensive antihypertensive treatment goals (additional reduction of 5 mmHg) for patients with hypertension at high cardiovascular risk who are already within the intensive treatment range (SBP &#x0003c; 130 mmHg), with the objective of further reducing future major cardiovascular events (myocardial infarction, stroke, and death). This is a strong recommendation with high certainty of evidence.</p><sec sec-type="intro"><title>Introduction</title><p>Hypertension is currently is currently a major health challenge that substantially contributes to cardiovascular disease rates worldwide. It is a major risk factor for morbidity and mortality, affecting more than 1 billion people and accounting for approximately 9.4 million deaths annually.<sup><xref rid="B1" ref-type="bibr">1</xref></sup> Not only does hypertension increase the risk of cardiovascular complications, it also imposes a considerable economic burden on health systems, especially in low- and middle-income countries.<sup><xref rid="B2" ref-type="bibr">2</xref></sup> In Brazil, hypertension is also a major public health problem, affecting approximately one third of the adult population.<sup><xref rid="B3" ref-type="bibr">3</xref></sup> It is responsible for a significant proportion of cases of myocardial infarction and stroke, which are the leading causes of death in Brazil.<sup><xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B5" ref-type="bibr">5</xref></sup> Hypertension also exerts a substantial influence on the Brazilian Unified Health System (SUS, acronym in Portuguese), resulting in increased health costs, significant loss of work days, and early retirement.<sup><xref rid="B6" ref-type="bibr">6</xref></sup> There is a growing need for effective public health interventions aimed at prevention, early detection, and management of the disease.<sup><xref rid="B7" ref-type="bibr">7</xref></sup> It is crucial to address this challenge in order to improve health and reduce chronic disease levels in Brazil.</p><p>Antihypertensive treatment plays a crucial role in disease management and in reducing the risk associated with cardiovascular events, usually involving a combination of lifestyle interventions and pharmacological treatments.<sup><xref rid="B7" ref-type="bibr">7</xref></sup> There is currently a debate regarding the optimal goals to be achieved in hypertension. Intensive control strategies, which aim for lower blood pressure (BP) goals, have shown a significant reduction in the incidence of critical events in high-risk patients in clinical trials such as SPRINT.<sup><xref rid="B8" ref-type="bibr">8</xref></sup> Nonetheless, this approach also involves a potential increase in the risk of adverse events, such as hypotension, acute kidney injury, and electrolyte imbalances, which can lead to unfavorable outcomes, especially in elderly or frail patients.<sup><xref rid="B9" ref-type="bibr">9</xref></sup> On the other hand, conventional treatment, which follows more moderate BP goals, may not provide the same level of cardiovascular and renal protection.<sup><xref rid="B8" ref-type="bibr">8</xref></sup>This discussion highlights the importance of individualized treatments, which consider patients&#x02019; general health status, in addition to comorbidities and the possibility of treatment-related adverse effects.</p><p>With the objective of clarifying the best strategy in relation to BP goals in patients with hypertension, considering the best current scientific evidence, the Brazilian Society of Cardiology (SBC) has developed a clinical recommendation on this topic.</p></sec><sec sec-type="methods"><title>Methods</title><p>In order to develop the clinical recommendation, a systematic review was carried out. The following research question was structured in the PICO (patient/population, intervention, comparison, and outcome) format: In patients with hypertension, what is the difference between pharmacological treatment with more intensive BP control goals (&#x0003c; 130/80 mmHg) compared to the usual control goals (&#x02265; 130/80 mmHg), specifically in relation to critical and important outcomes, such as death, stroke, myocardial infarction, progression to stage 4 or 5 kidney failure, need for dialysis, or kidney transplant? The study protocol was registered in the PROSPERO database, under number CRD42024545853.</p><p>This document used rapid systematic review methodology, which belongs to the family of systematic reviews. This tool was developed over the last decade with the aim of maintaining methodological rigor in seeking the best possible evidence, but with modifications that speed up the execution time. These reviews generally inform medical societies or health institutions regarding the best evidence available, based on a question in the PICO format, in a sensitive, transparent, and systematic manner. Leading institutions in the area of methodology have described the methods for this type of systematic review.<sup><xref rid="B10" ref-type="bibr">10</xref>-<xref rid="B12" ref-type="bibr">12</xref></sup></p><p>An initial search for systematic reviews on the PICO question was carried out in three databases: Medline, Embase, and Cochrane Library. Details of the search strategies are provided in the supplementary material (<inline-supplementary-material xlink:href="0066-782X-abc-122-3-e20240761-suppl01-en.pdf" id="d67e3443" content-type="local-data">Table S1</inline-supplementary-material>). Two researchers independently performed study selection and extraction of baseline characteristics from the documents selected for full reading (<inline-supplementary-material xlink:href="0066-782X-abc-122-3-e20240761-suppl01-en.pdf" id="d67e3446" content-type="local-data">Tables S2 and S3</inline-supplementary-material>). However, among the systematic reviews found, which covered the years 2019 to 2024, none exactly addressed the PICO question of interest, except for the paper by Sakima et al.<sup><xref rid="B13" ref-type="bibr">13</xref></sup> Their publication included searches for studies up to March 2018, retrieving 9 articles that compared the intensive BP goal (&#x0003c; 130/80 mmHg) with the usual goal and evaluated cardiovascular events as an outcome. The authors decided to update the search for this systematic review and perform a new meta-analysis with the data extracted from the primary studies.</p><p>A second search for randomized controlled trials (RCTs) was performed to update the selected reference document, covering the period March 2018 to May 2024 in the same databases as the first search. Details of the search strategies are provided in the supplementary material (<inline-supplementary-material xlink:href="0066-782X-abc-122-3-e20240761-suppl01-en.pdf" id="d67e3455" content-type="local-data">Table 4S</inline-supplementary-material>). Articles selected for full-text review were considered for inclusion if they met the following criteria: (1) being RCTs; (2) presenting risk estimates to assess the impact of intensive BP goals versus usual BP goals; (3) presenting at least one of the following outcomes, described numerically: all-cause mortality, stroke, myocardial infarction, progression to stage 4 or 5 renal failure, need for dialysis, or kidney transplantation; (4) including patients aged 18 years or older. There were no language restrictions on study selection.</p><p>Two researchers were responsible for the selection, extraction, and quality assessment of all final articles. The Cochrane Collaboration&#x02019;s Risk of Bias 2 (RoB 2) tool was used to assess the risk of bias.<sup><xref rid="B14" ref-type="bibr">14</xref></sup> The strength of recommendations and the certainty of evidence were assessed following the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology<sup><xref rid="B15" ref-type="bibr">15</xref></sup> (<xref rid="t2001" ref-type="table">Tables 2</xref> and <xref rid="t3001" ref-type="table">3</xref>). A detailed description of the methodology applied in this systematic review can be found in the supplementary material. Publication bias was not assessed because there were fewer than 10 original studies.</p><p>
<table-wrap position="float" id="t2001"><label>Table 2</label><caption><title>&#x02013; Risk of bias in the primary studies according to the Cochrane Collaboration&#x02019;s RoB 2.0 tool</title></caption><table frame="hsides" rules="groups"><colgroup width="10%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Study</th><th rowspan="1" colspan="1">Intervention</th><th rowspan="1" colspan="1">Comparator</th><th rowspan="1" colspan="1">Outcome</th><th rowspan="1" colspan="1">D1</th><th rowspan="1" colspan="1">D2</th><th rowspan="1" colspan="1">D3</th><th rowspan="1" colspan="1">D4</th><th rowspan="1" colspan="1">D5</th><th align="left" style="font-weight:normal" rowspan="1" colspan="1">&#x000a0;</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Schrier</td><td align="center" rowspan="1" colspan="1">Intensive treatment</td><td align="center" rowspan="1" colspan="1">Usual treatment</td><td align="center" rowspan="1" colspan="1">CV events</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04-en.jpg"/>
</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04-en.jpg"/>
</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt05-en.jpg"/>
</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04-en.jpg"/>
</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04-en.jpg"/>
</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt05a-en.jpg"/>
</td></tr><tr><td rowspan="1" colspan="1">ESTACIO</td><td align="center" rowspan="1" colspan="1">Intensive treatment</td><td align="center" rowspan="1" colspan="1">Usual treatment</td><td align="center" rowspan="1" colspan="1">CV events</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04-en.jpg"/>
</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04-en.jpg"/>
</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04-en.jpg"/>
</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt06-en.jpg"/>
</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04-en.jpg"/>
</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt06a-en.jpg"/>
</td></tr><tr><td rowspan="1" colspan="1">CardioSis</td><td align="center" rowspan="1" colspan="1">Intensive treatment</td><td align="center" rowspan="1" colspan="1">Usual treatment</td><td align="center" rowspan="1" colspan="1">CV events</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt05-en.jpg"/>
</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt06-en.jpg"/>
</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04-en.jpg"/>
</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt06-en.jpg"/>
</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt06-en.jpg"/>
</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt05a-en.jpg"/>
</td></tr><tr><td rowspan="1" colspan="1">Appel</td><td align="center" rowspan="1" colspan="1">Intensive treatment</td><td align="center" rowspan="1" colspan="1">Usual treatment</td><td align="center" rowspan="1" colspan="1">CV events</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt06-en.jpg"/>
</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt06-en.jpg"/>
</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04-en.jpg"/>
</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04-en.jpg"/>
</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt06-en.jpg"/>
</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt06a-en.jpg"/>
</td></tr><tr><td rowspan="1" colspan="1">ACCORD</td><td align="center" rowspan="1" colspan="1">Intensive treatment</td><td align="center" rowspan="1" colspan="1">Usual treatment</td><td align="center" rowspan="1" colspan="1">CV events</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04-en.jpg"/>
</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt06-en.jpg"/>
</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04-en.jpg"/>
</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04-en.jpg"/>
</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04-en.jpg"/>
</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04a-en.jpg"/>
</td></tr><tr><td rowspan="1" colspan="1">SPS3</td><td align="center" rowspan="1" colspan="1">Intensive treatment</td><td align="center" rowspan="1" colspan="1">Usual treatment</td><td align="center" rowspan="1" colspan="1">CV events</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04-en.jpg"/>
</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04-en.jpg"/>
</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt06-en.jpg"/>
</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04-en.jpg"/>
</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04-en.jpg"/>
</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt06a-en.jpg"/>
</td></tr><tr><td rowspan="1" colspan="1">SPRINT</td><td align="center" rowspan="1" colspan="1">Intensive treatment</td><td align="center" rowspan="1" colspan="1">Usual treatment</td><td align="center" rowspan="1" colspan="1">CV events</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04-en.jpg"/>
</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04-en.jpg"/>
</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04-en.jpg"/>
</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04-en.jpg"/>
</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04-en.jpg"/>
</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04a-en.jpg"/>
</td></tr><tr><td rowspan="1" colspan="1">HOMED-BP</td><td align="center" rowspan="1" colspan="1">Intensive treatment</td><td align="center" rowspan="1" colspan="1">Usual treatment</td><td align="center" rowspan="1" colspan="1">CV events</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04-en.jpg"/>
</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt05-en.jpg"/>
</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt05-en.jpg"/>
</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04-en.jpg"/>
</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04-en.jpg"/>
</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt05a-en.jpg"/>
</td></tr><tr><td rowspan="1" colspan="1">STEP - Zhang</td><td align="center" rowspan="1" colspan="1">Intensive treatment</td><td align="center" rowspan="1" colspan="1">Usual treatment</td><td align="center" rowspan="1" colspan="1">CV events</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04-en.jpg"/>
</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04-en.jpg"/>
</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04-en.jpg"/>
</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04-en.jpg"/>
</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04-en.jpg"/>
</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04a-en.jpg"/>
</td></tr></tbody></table><table-wrap-foot><fn id="TFN2001"><p>
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt04-en.jpg"/>: Low risk; <inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt06-en.jpg"/>: Moderate risk; <inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt05-en.jpg"/>: High risk. D1: Randomization; D2: Deviation from treatment; D3: Missing data; D4: Outcome measurement; D5 Selection of reported results. CV: cardiovascular.</p></fn></table-wrap-foot></table-wrap>
</p><p>
<table-wrap position="float" id="t3001"><label>Table 3</label><caption><title>&#x02013; Summary of findings, according to GRADE methodology</title></caption><table frame="hsides" rules="groups"><colgroup width="17%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Outcome</th><th colspan="2" rowspan="1">Absolute effect (95% CI)</th><th rowspan="2" colspan="1">Relative effect (95% CI)</th><th rowspan="2" colspan="1">Number of participants (studies)</th><th rowspan="2" colspan="1">Certainty of evidence</th></tr><tr><th rowspan="1" colspan="1">Risk with usual treatment</th><th rowspan="1" colspan="1">Risk with intensive treatment (&#x0003c; 130/80 mmHg)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">CV events (death, AMI, and stroke)</td><td align="center" rowspan="1" colspan="1">89 per 1000</td><td align="center" rowspan="1" colspan="1">77 per 1000</td><td align="center" rowspan="1" colspan="1">RR 0.87 (0.80 to 0.94)</td><td align="center" rowspan="1" colspan="1">32,749 (9 RCTs)</td><td align="center" rowspan="1" colspan="1">High</td></tr><tr><td rowspan="1" colspan="1">Death</td><td align="center" rowspan="1" colspan="1">39 per 1000</td><td align="center" rowspan="1" colspan="1">36 per 1000</td><td align="center" rowspan="1" colspan="1">RR 0.93 (0.80 to 1.09)</td><td align="center" rowspan="1" colspan="1">32,029 (9 RCTs)</td><td align="center" rowspan="1" colspan="1">High</td></tr></tbody></table><table-wrap-foot><fn id="TFN3001"><p>AMI: acute myocardial infarction; CV: cardiovascular; RCTs: randomized controlled trials.</p></fn></table-wrap-foot></table-wrap>
</p><p>The clinical recommendations were defined by means of consensus during a reunion of a recommendation panel made up of professionals appointed by the SBC. A threshold of 5% was considered as a minimum important difference for the intervention to be considered clinically relevant.</p><p>The project was supervised and funded in its entirety by the SBC. The preparation of the systematic review was conducted by an independent team of methodologists.</p></sec><sec sec-type="results"><title>Results</title><p>The 9 articles included in the reference meta-analysis,<sup><xref rid="B13" ref-type="bibr">13</xref></sup> comparing the intensive antihypertensive treatment goal (&#x0003c; 130/80 mmHg) with the standard treatment goal, were assessed for inclusion in this new meta-analysis. One of them was excluded because it did not present the relative risks of interest,<sup><xref rid="B16" ref-type="bibr">16</xref></sup> and the remaining 8 publications were included.<sup><xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B17" ref-type="bibr">17</xref>-<xref rid="B23" ref-type="bibr">23</xref></sup></p><p>As a result of the second literature search, with the objective of identifying new RCTs published after March 2018, 2,061 citations were initially screened. Only 2 of these studies were selected for full-text review, resulting in the inclusion of an additional RCT in the updated meta-analysis<sup><xref rid="B24" ref-type="bibr">24</xref></sup> and the exclusion of the second article because it was not an original RCT.<sup><xref rid="B25" ref-type="bibr">25</xref></sup></p><p>The main characteristics of the 9 primary studies included in this meta-analysis are displayed in <xref rid="t1001" ref-type="table">Table 1</xref>. All extracted characteristics are available in the supplementary material (<inline-supplementary-material xlink:href="0066-782X-abc-122-3-e20240761-suppl01-en.pdf" id="d67e3922" content-type="local-data">Table 5S</inline-supplementary-material>).</p><p>
<table-wrap position="float" id="t1001"><label>Table 1</label><caption><title>&#x02013; Main characteristics of the primary studies</title></caption><table frame="hsides" rules="groups"><colgroup width="8%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Main author</th><th rowspan="1" colspan="1">Year of publication</th><th rowspan="1" colspan="1">Population characteristics</th><th rowspan="1" colspan="1">BP goal in intensive group</th><th rowspan="1" colspan="1">Baseline systolic BP (mmHg)</th><th rowspan="1" colspan="1">Baseline diastolic BP (mmHg)</th><th rowspan="1" colspan="1">Number of participants</th><th rowspan="1" colspan="1">Events</th><th rowspan="1" colspan="1">Mean age</th><th rowspan="1" colspan="1">Percentage women</th><th rowspan="1" colspan="1">Country</th><th rowspan="1" colspan="1">Missing data. n(%)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">#02 Schrier</td><td align="center" rowspan="1" colspan="1">2002</td><td align="center" rowspan="1" colspan="1">Normotensive patients with type 2 diabetes</td><td align="center" rowspan="1" colspan="1">&#x0003c;130/80 mmHg</td><td align="center" rowspan="1" colspan="1">141.5</td><td align="center" rowspan="1" colspan="1">96</td><td align="center" rowspan="1" colspan="1">480</td><td align="center" rowspan="1" colspan="1">89</td><td align="center" rowspan="1" colspan="1">57</td><td align="center" rowspan="1" colspan="1">49%</td><td align="center" rowspan="1" colspan="1">USA</td><td align="center" rowspan="1" colspan="1">55(11)</td></tr><tr><td rowspan="1" colspan="1">#3 Estacio</td><td align="center" rowspan="1" colspan="1">2006</td><td align="center" rowspan="1" colspan="1">Normotensive patients with type 2 diabetes and normo- or microalbuminuria</td><td align="center" rowspan="1" colspan="1">&#x0003c; 75 mmHg (PAD)</td><td align="center" rowspan="1" colspan="1">126</td><td align="center" rowspan="1" colspan="1">84</td><td align="center" rowspan="1" colspan="1">129</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">56</td><td align="center" rowspan="1" colspan="1">47%</td><td align="center" rowspan="1" colspan="1">USA</td><td align="center" rowspan="1" colspan="1">10(7)</td></tr><tr><td rowspan="1" colspan="1">#4 CardioSis</td><td align="center" rowspan="1" colspan="1">2009</td><td align="center" rowspan="1" colspan="1">Hypertensive patients with metabolic syndrome</td><td align="center" rowspan="1" colspan="1">&#x0003c;130 mmHg</td><td align="center" rowspan="1" colspan="1">144.0</td><td align="center" rowspan="1" colspan="1">92.0</td><td align="center" rowspan="1" colspan="1">1111</td><td align="center" rowspan="1" colspan="1">97</td><td align="center" rowspan="1" colspan="1">55.6</td><td align="center" rowspan="1" colspan="1">43%</td><td align="center" rowspan="1" colspan="1">Italy</td><td align="center" rowspan="1" colspan="1">27(2)</td></tr><tr><td rowspan="1" colspan="1">#5 Appel</td><td align="center" rowspan="1" colspan="1">2010</td><td align="center" rowspan="1" colspan="1">African American patients with hypertensive nephrosclerosis</td><td align="center" rowspan="1" colspan="1">&#x0003c;130/80 mmHg</td><td align="center" rowspan="1" colspan="1">142</td><td align="center" rowspan="1" colspan="1">95</td><td align="center" rowspan="1" colspan="1">1094</td><td align="center" rowspan="1" colspan="1">120</td><td align="center" rowspan="1" colspan="1">55.3</td><td align="center" rowspan="1" colspan="1">39%</td><td align="center" rowspan="1" colspan="1">USA</td><td align="center" rowspan="1" colspan="1">0(0)</td></tr><tr><td rowspan="1" colspan="1">#6 ACCORD</td><td align="center" rowspan="1" colspan="1">2010</td><td align="center" rowspan="1" colspan="1">Patients with type 2 diabetes and hypertension</td><td align="center" rowspan="1" colspan="1">&#x0003c;120 mmHg</td><td align="center" rowspan="1" colspan="1">139.3</td><td align="center" rowspan="1" colspan="1">76.0</td><td align="center" rowspan="1" colspan="1">4733</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">62.2</td><td align="center" rowspan="1" colspan="1">38%</td><td align="center" rowspan="1" colspan="1">USA</td><td align="center" rowspan="1" colspan="1">232(4.9)</td></tr><tr><td rowspan="1" colspan="1">#7 SPS3</td><td align="center" rowspan="1" colspan="1">2013</td><td align="center" rowspan="1" colspan="1">Patients with recent lacunar stroke</td><td align="center" rowspan="1" colspan="1">&#x0003c;130 mmHg</td><td align="center" rowspan="1" colspan="1">143.4</td><td align="center" rowspan="1" colspan="1">78.2</td><td align="center" rowspan="1" colspan="1">3020</td><td align="center" rowspan="1" colspan="1">377</td><td align="center" rowspan="1" colspan="1">63</td><td align="center" rowspan="1" colspan="1">37%</td><td align="center" rowspan="1" colspan="1">USA</td><td align="center" rowspan="1" colspan="1">550(18.4)</td></tr><tr><td rowspan="1" colspan="1">#8 SPRINT</td><td align="center" rowspan="1" colspan="1">2015</td><td align="center" rowspan="1" colspan="1">Hypertensive patients with increased cardiovascular risk</td><td align="center" rowspan="1" colspan="1">&#x0003c;120 mmHg</td><td align="center" rowspan="1" colspan="1">139.7</td><td align="center" rowspan="1" colspan="1">78.1</td><td align="center" rowspan="1" colspan="1">9361</td><td align="center" rowspan="1" colspan="1">562</td><td align="center" rowspan="1" colspan="1">67.9</td><td align="center" rowspan="1" colspan="1">36%</td><td align="center" rowspan="1" colspan="1">USA</td><td align="center" rowspan="1" colspan="1">986(10.5)</td></tr><tr><td rowspan="1" colspan="1">#9 HOMED-BP</td><td align="center" rowspan="1" colspan="1">2018</td><td align="center" rowspan="1" colspan="1">Japanese patients with hypertension over 40 years of age</td><td align="center" rowspan="1" colspan="1">&#x0003c;125/80</td><td align="center" rowspan="1" colspan="1">154</td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">3518</td><td align="center" rowspan="1" colspan="1">51</td><td align="center" rowspan="1" colspan="1">59.6</td><td align="center" rowspan="1" colspan="1">50%</td><td align="center" rowspan="1" colspan="1">Japan</td><td align="center" rowspan="1" colspan="1">710(20)</td></tr><tr><td rowspan="1" colspan="1">#10 Zhang</td><td align="center" rowspan="1" colspan="1">2021</td><td align="center" rowspan="1" colspan="1">Chinese patients with hypertension between 60 and 80 years of age</td><td align="center" rowspan="1" colspan="1">110-130 mmHg</td><td align="center" rowspan="1" colspan="1">146.1</td><td align="center" rowspan="1" colspan="1">86.1</td><td align="center" rowspan="1" colspan="1">8511</td><td align="center" rowspan="1" colspan="1">355</td><td align="center" rowspan="1" colspan="1">66.2</td><td align="center" rowspan="1" colspan="1">54%</td><td align="center" rowspan="1" colspan="1">China</td><td align="center" rowspan="1" colspan="1">234(2.7)</td></tr><tr><td rowspan="1" colspan="1"><bold>Main author</bold></td><td align="center" rowspan="1" colspan="1"><bold>Year of publication</bold></td><td align="center" rowspan="1" colspan="1"><bold>Primary outcomes</bold></td><td align="center" rowspan="1" colspan="1"><bold>CV events, intensive group</bold></td><td align="center" rowspan="1" colspan="1"><bold>CV events, usual group</bold></td><td align="center" rowspan="1" colspan="1"><bold>Death, intensive group</bold></td><td align="center" rowspan="1" colspan="1"><bold>Death, usual group</bold></td><td align="center" rowspan="1" colspan="1"><bold>AMI, intensive group</bold></td><td align="center" rowspan="1" colspan="1"><bold>AMI, usual group</bold></td><td align="center" rowspan="1" colspan="1"><bold>Stroke, intensive group</bold></td><td align="center" rowspan="1" colspan="1"><bold>Stroke, usual group</bold></td><td align="center" rowspan="1" colspan="1"><bold>RoB 2.0</bold></td></tr><tr><td rowspan="1" colspan="1">#02 Schrier</td><td align="center" rowspan="1" colspan="1">2002</td><td align="center" rowspan="1" colspan="1">Altered creatinine clearance</td><td align="center" rowspan="1" colspan="1">41/237</td><td align="center" rowspan="1" colspan="1">48/243</td><td align="center" rowspan="1" colspan="1">18/237</td><td align="center" rowspan="1" colspan="1">20/243</td><td align="center" rowspan="1" colspan="1">19/237</td><td align="center" rowspan="1" colspan="1">15/243</td><td align="center" rowspan="1" colspan="1">4/237</td><td align="center" rowspan="1" colspan="1">13/243</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt01-en.jpg"/>
</td></tr><tr><td rowspan="1" colspan="1">#3 Estacio</td><td align="center" rowspan="1" colspan="1">2006</td><td align="center" rowspan="1" colspan="1">Altered urinary albumin excretion</td><td align="center" rowspan="1" colspan="1">3/66</td><td align="center" rowspan="1" colspan="1">2/63</td><td align="center" rowspan="1" colspan="1">1/66</td><td align="center" rowspan="1" colspan="1">0/63</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt02-en.jpg"/>
</td></tr><tr><td rowspan="1" colspan="1">#4 CardioSis</td><td align="center" rowspan="1" colspan="1">2009</td><td align="center" rowspan="1" colspan="1">Reduced left ventricular mass index</td><td align="center" rowspan="1" colspan="1">12/557</td><td align="center" rowspan="1" colspan="1">20/553</td><td align="center" rowspan="1" colspan="1">4/557</td><td align="center" rowspan="1" colspan="1">5/553</td><td align="center" rowspan="1" colspan="1">4/557</td><td align="center" rowspan="1" colspan="1">6/553</td><td align="center" rowspan="1" colspan="1">4/557</td><td align="center" rowspan="1" colspan="1">9/553</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt01-en.jpg"/>
</td></tr><tr><td rowspan="1" colspan="1">#5 Appel</td><td align="center" rowspan="1" colspan="1">2010</td><td align="center" rowspan="1" colspan="1">Composite outcome of death, end-stage renal disease, or reduced glomerular filtration rate</td><td align="center" rowspan="1" colspan="1">83/540</td><td align="center" rowspan="1" colspan="1">99/554</td><td align="center" rowspan="1" colspan="1">38/540</td><td align="center" rowspan="1" colspan="1">47/554</td><td align="center" rowspan="1" colspan="1">19/540</td><td align="center" rowspan="1" colspan="1">23/554</td><td align="center" rowspan="1" colspan="1">26/540</td><td align="center" rowspan="1" colspan="1">29/554</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt02-en.jpg"/>
</td></tr><tr><td rowspan="1" colspan="1">#6 ACCORD</td><td align="center" rowspan="1" colspan="1">2010</td><td align="center" rowspan="1" colspan="1">Composite outcome of AMI, stroke, and death</td><td align="center" rowspan="1" colspan="1">310/2363</td><td align="center" rowspan="1" colspan="1">345/2371</td><td align="center" rowspan="1" colspan="1">150/2363</td><td align="center" rowspan="1" colspan="1">144/2371</td><td align="center" rowspan="1" colspan="1">126/2363</td><td align="center" rowspan="1" colspan="1">146/2371</td><td align="center" rowspan="1" colspan="1">34/2363</td><td align="center" rowspan="1" colspan="1">55/2371</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt03-en.jpg"/>
</td></tr><tr><td rowspan="1" colspan="1">#7 SPS3</td><td align="center" rowspan="1" colspan="1">2013</td><td align="center" rowspan="1" colspan="1">Recurrent stroke</td><td align="center" rowspan="1" colspan="1">267/1501</td><td align="center" rowspan="1" colspan="1">293/1519</td><td align="center" rowspan="1" colspan="1">106/1501</td><td align="center" rowspan="1" colspan="1">101/1519</td><td align="center" rowspan="1" colspan="1">36/1501</td><td align="center" rowspan="1" colspan="1">40/1519</td><td align="center" rowspan="1" colspan="1">125/1501</td><td align="center" rowspan="1" colspan="1">152/1519</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt02-en.jpg"/>
</td></tr><tr><td rowspan="1" colspan="1">#8 SPRINT</td><td align="center" rowspan="1" colspan="1">2015</td><td align="center" rowspan="1" colspan="1">Composite outcome of AMI, stroke, cardiovascular death, ACS, and HF</td><td align="center" rowspan="1" colspan="1">314/4678</td><td align="center" rowspan="1" colspan="1">396/4683</td><td align="center" rowspan="1" colspan="1">155/4678</td><td align="center" rowspan="1" colspan="1">210/4683</td><td align="center" rowspan="1" colspan="1">97/4678</td><td align="center" rowspan="1" colspan="1">116/4683</td><td align="center" rowspan="1" colspan="1">62/4678</td><td align="center" rowspan="1" colspan="1">70/4683</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt03-en.jpg"/>
</td></tr><tr><td rowspan="1" colspan="1">#9 HOMED-BP</td><td align="center" rowspan="1" colspan="1">2018</td><td align="center" rowspan="1" colspan="1">Composite outcome of cardiovascular death, AMI, and stroke</td><td align="center" rowspan="1" colspan="1">72/1759</td><td align="center" rowspan="1" colspan="1">75/1759</td><td align="center" rowspan="1" colspan="1">27/1759</td><td align="center" rowspan="1" colspan="1">31/1759</td><td align="center" rowspan="1" colspan="1">25/1759 (***)</td><td align="center" rowspan="1" colspan="1">28/1759 (***)</td><td align="center" rowspan="1" colspan="1">20/1759</td><td align="center" rowspan="1" colspan="1">16/1759</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt01-en.jpg"/>
</td></tr><tr><td rowspan="1" colspan="1">#10 Zhang</td><td align="center" rowspan="1" colspan="1">2021</td><td align="center" rowspan="1" colspan="1">Composite outcome of cardiovascular events and death</td><td align="center" rowspan="1" colspan="1">170/4243</td><td align="center" rowspan="1" colspan="1">217/4268</td><td align="center" rowspan="1" colspan="1">67/4243</td><td align="center" rowspan="1" colspan="1">64/4268</td><td align="center" rowspan="1" colspan="1">55/4243 (**)</td><td align="center" rowspan="1" colspan="1">82/4268 (**)</td><td align="center" rowspan="1" colspan="1">48/4243</td><td align="center" rowspan="1" colspan="1">71/4268</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="0066-782X-abc-122-3-e20240761-gt03-en.jpg"/>
</td></tr></tbody></table><table-wrap-foot><fn id="TFN1001"><p>(**) ACS, not isolated AMI. (***) Not only AMI, ischemic heart disease included death from angina pectoris, cardiac arrest, and nonfatal myocardial infarction. ACS: acute coronary syndrome; AMI: acute myocardial infarction; BP: blood pressure; CV: cardiovascular; HF: heart failure</p></fn></table-wrap-foot></table-wrap>
</p><p>The effect for the primary composite outcome, obtained by summarizing the data from the 9 primary studies, is shown in <xref rid="f02001" ref-type="fig">Figure 1</xref>. There was a 13% reduction in events, favoring the strategy of more intensive antihypertensive treatment goals. For the same outcome, when only studies with low risk of bias were included (<xref rid="f03001" ref-type="fig">Figure 2</xref>), a 17% reduction in events was observed, also favoring the strategy of more intensive antihypertensive treatment goals. The certainty of evidence for this analysis was classified as high, according to the GRADE methodology.</p><p>
<fig position="float" id="f02001"><label>Figure 1</label><caption><title>&#x02013; Meta-analysis for the primary composite outcome, defined as myocardial infarction, stroke, and all-cause mortality.</title></caption><graphic xlink:href="0066-782X-abc-122-3-e20240761-gf02-en" position="float"/><attrib>Heterogeneity: I<sup>2</sup>= 0%; t<sup>2</sup> = 0.0013; p = 0.60</attrib></fig>
</p><p>
<fig position="float" id="f03001"><label>Figure 2</label><caption><title>&#x02013; Meta-analysis of the primary composite outcome, defined as myocardial infarction, stroke, and all-cause mortality, assessed only for studies with low risk of bias.</title></caption><graphic xlink:href="0066-782X-abc-122-3-e20240761-gf03-en" position="float"/><attrib>Heterogeneity: I<sup>2</sup>= 0%; t<sup>2</sup> = 0.0005; p = 0.38</attrib></fig>
</p><p>When these 3 outcomes were assessed separately, they showed a reduction in myocardial infarction and stroke, favoring the strategy of more intensive goals, with no significant difference observed for all-cause mortality (Figure 1S).</p><p>The outcome of progression to kidney disease was assessed in 4 of the included studies, but only 2 provided numerical data. Due to the low number of studies and differences in the definitions of kidney progression, the authors did not include this outcome in the primary assessment and did not perform a meta-analysis for this individual event.</p><p>Two additional systematic reviews assessed for full reading in the first search answered PICO questions with slight differences in relation to this review&#x02019;s original scientific question. They were considered highly relevant to the health system by the authors, and they supported two additional clinical recommendations in this document.<sup><xref rid="B26" ref-type="bibr">26</xref>,<xref rid="B27" ref-type="bibr">27</xref></sup> Both publications were considered to have good technical quality by the authors, and the AMSTAR 2 quality assessment<sup><xref rid="B28" ref-type="bibr">28</xref></sup> penalized them only in relation to characteristics that did not compromise central information. <inline-supplementary-material xlink:href="0066-782X-abc-122-3-e20240761-suppl01-en.pdf" id="d67e4542" content-type="local-data">Table 6S</inline-supplementary-material> displays the AMSTAR 2 quality assessment of both additional systematic reviews used for supplemental clinical recommendations.</p><p>
<inline-supplementary-material xlink:href="0066-782X-abc-122-3-e20240761-suppl01-en.pdf" id="d67e4548" content-type="local-data">Table 7S</inline-supplementary-material> describes this document&#x02019;s PRISMA.</p></sec><sec sec-type="discussion"><title>Discussion</title><p>Hypertension is one of the main modifiable risk factors for premature death. Therefore, it is of paramount importance to determine whether more intensive BP reduction goals offer additional benefits for reducing cardiovascular complications, in line with the educational mission of the SBC. This review offers a conclusive answer to this gap in clinical practice.</p><p>Defining a target value for antihypertensive treatment has been a challenge in the scientific literature due to the variability of the goals proposed in different studies. Although a cutoff point of 120/80 mmHg can be considered, RCTs that aimed at this more rigorous target often faced difficulties in achieving these results. For this reason, this systematic review opted to include studies in which the intervention arm aimed at a BP below 130/80 mmHg, a more achievable objective in real clinical practice.</p><p>In the initial literature search, with the objective of identifying systematic reviews that addressed the predefined PICO question, no document was found that could provide an updated answer. This led to the decision to update the article by Sakima et al.<sup><xref rid="B14" ref-type="bibr">14</xref></sup></p><p>Based on the results demonstrated in this review, which included data from more than 34,000 individuals, the clinical benefit of stricter BP control goals for the population of people with hypertension has been well established. However, there was still uncertainty as to whether all cardiovascular risk spectra would benefit from this effect. Among the 9 studies included, 5 of them (with more than 6,000 patients) had a mean age below 60 years and a significant proportion of women (40% or more). This allows us to conclude that a substantial proportion of these participants were in the low-risk category for cardiovascular events (estimated risk &#x0003c; 7.5% over 10 years). On the other hand, the remaining 4 studies, which included mostly male patients over 60 years, adequately represented the other extreme end of exposure, encompassing patients with high cardiovascular risk (estimated risk &#x0003e; 15% over 10 years). Combining these data, we can assume that these subgroups were well represented in the studies that observed an important benefit in event reduction.</p><p>Another relevant question that arises is whether further reductions to values of 120/80 mmHg or even lower, particularly in patients with higher cardiovascular risk and lower likelihood of side effects, could result in additional clinical benefits (and would be worth recommending, if put into practice). Based on individual data meta-analysis from the 2021 Blood Pressure Lowering Treatment Trialists&#x02019; Collaboration, for any initial BP range (even in individuals with systolic values below 120 mmHg), a reduction of 5 mmHg leads to an 11% reduction in cardiovascular events.<sup><xref rid="B28" ref-type="bibr">28</xref></sup> For these high-risk individuals, pursuing the goals of strict control proposed by the SPRINT<sup><xref rid="B8" ref-type="bibr">8</xref></sup> and ACCORD<sup><xref rid="B22" ref-type="bibr">22</xref></sup> studies may be an advantageous therapeutic option. The risk of side effects, number of medications used (adherence), and additional costs must be taken into account and compared with the significant reduction in critical cardiovascular events. This systematic review served as a reference for the third clinical recommendation in this document.</p><p>Stricter BP control goals always raise concerns about adverse events, especially in very elderly or frail patients. However, a recent meta-analysis involving 20,895 elderly individuals demonstrated that a strategy of intensive BP control goals resulted in a 29% reduction in the main cardiovascular events, with no evidence of an increase in serious adverse reactions or worsening of renal function.<sup><xref rid="B27" ref-type="bibr">27</xref></sup> These findings further support the implementation of stricter hypertension control for the general population, regardless of age. Nonetheless, this recommendation does not eliminate the need to consider the individual circumstances of each patient and to establish less intensive goals for patients who are frail, have a limited life expectancy, or possess characteristics that may increase the risk of adverse effects. This systematic review served as a reference for the second clinical recommendation in this document.</p><p>Regarding possible adverse events of antihypertensive treatment, there is also discussion about the J-curve phenomenon. This refers to the observation that both excessively high and excessively low BP levels are associated with an increased risk of cardiovascular complications, forming a J-shaped curve when plotted on a graph. This phenomenon is particularly observed with diastolic BP and its association with coronary artery disease and other cardiovascular events. The concept of the J-curve relationship between BP and cardiovascular outcomes was first proposed in the 1970s,<sup><xref rid="B30" ref-type="bibr">30</xref></sup> and it was subsequently verified in several observational studies, such as the Framingham Study.<sup><xref rid="B31" ref-type="bibr">31</xref></sup> Based on the same systematic review carried out by the Blood Pressure Lowering Treatment Trialists&#x02019; Collaboration group in 2021, bringing together 48 RCTs (which have more robust certainty of evidence than observational studies), when we evaluated the population with previous cardiovascular disease and reductions in systolic BP beyond 120 mmHg, no increase was shown in cardiovascular events. On the contrary, even in this population with very high risk, a decrease in primary outcomes was observed with very intensive BP reduction goals, contradicting the hypothesis of the J-curve phenomenon.</p><p>An additional relevant discussion is whether the method of measuring BP could influence the clinical effect results observed. The SPRINT study used a method that involved taking 3 BP measurements during an office visit, with the patient seated, after a 5-minute rest period, using an automated measurement system (Model 907, Omron Healthcare), without the presence of a physician or other health care professional. This procedure has been criticized for differing from those used in other studies, raising concerns about the reproducibility of its results. However, a study carried out shortly after SPRINT demonstrated, through interviews with its participants, that this technique was implemented in less than half of the patients, with no differences in clinical outcomes between the groups based on the BP measurement method.<sup><xref rid="B32" ref-type="bibr">32</xref></sup> A second study compared the technique proposed in the SPRINT trial with BP measurements taken without prior rest. The results showed considerable variability in the agreement between values, suggesting that the SPRINT technique could lead to lower BP readings.<sup><xref rid="B33" ref-type="bibr">33</xref></sup> However, it was an observational study, conducted in a single center, with a small number of participants. These critiques are important, but they do not invalidate the results presented in this meta-analysis. Thus, one of the many advantages of conducting a systematic review is that it summarizes the results of several studies, minimizing the influence of a single isolated article on the final result. When performing sensitivity analysis excluding the SPRINT study, the clinical benefit of intensive BP reduction remained, showing an 11% reduction in events (Figure 2S).</p><p>A recent systematic review in the process of being published assessed a similar PICO question and reached similar results, corroborating the clinical recommendations suggested in this document by the SBC.<sup><xref rid="B34" ref-type="bibr">34</xref></sup> Whelton et al. (2024) observed a 22% reduction for the intensive systolic BP control goal (&#x0003c; 130 mmHg) for a composite outcome of stroke, coronary heart disease, heart failure, and cardiovascular death (hazard ratio [HR] = 0.78; 95% confidence interval [CI] = 0.70 to 0.87; heterogeneity: I<sup>2</sup> = 64.5%; p = 0.01). There was a statistical difference for the outcome of overall mortality (HR = 0.89; 95% CI = 0.79 to 0.99; heterogeneity: I<sup>2</sup> = 37%; p = 0.14), although there was some degree of imprecision for the clinical importance of this effect, as shown by the CI.</p><p>Finally, an RCT that was published while this paper was in the final composition phase also corroborates this systematic review&#x02019;s findings.<sup><xref rid="B35" ref-type="bibr">35</xref></sup> Liu et al. included 11,255 Chinese participants with high cardiovascular risk (4,359 with diabetes and 3,022 with prior stroke) who were assigned to intensive treatment (n = 5,624) or standard treatment (n = 5,631). The mean age was 64.6 years. The mean systolic BP during follow-up was 119.1 mmHg (standard deviation: 11.1) in the intensive treatment group and 134.8 mmHg (standard deviation: 10.5) in the standard treatment group. During a median of 3.4 years of follow-up, primary outcomes occurred in 547 (9.7%) participants in the intensive treatment group and 623 (11.1%) in the standard care group (HR = 0.88; 95% CI = 0.78 to 0.99). Severe adverse events of syncope were infrequent and occurred more frequently in the intensive treatment group (n = 24 [0.4%] of 5,624) than in the standard care group (n = 8 [0.1%] of 5,631; HR = 3.00, 95% CI = 1.35 to 6.68). There were no significant differences between groups regarding the severe adverse events of hypotension, electrolyte abnormality, injurious fall, or acute kidney injury.</p><p>Other factors, in addition to clinical benefits and harms, should be considered by a recommendation panel when making the final decision for a clinical recommendation, according to the GRADE Evidence-to-Decision framework. Cost is one of these factors. In Brazil, the main classes of antihypertensive medications are provided free of charge throughout the country by the Ministry of Health, which facilitates the implementation of the intensive strategy recommended in this document.<sup><xref rid="B36" ref-type="bibr">36</xref></sup></p><p>Patient adherence to prescribed medications can be challenging, as stricter BP control goals usually require increased medication use to achieve desired results. Strategies to improve adherence, such as simplifying dosing regimens (prescribing medications that require fewer doses per day),<sup><xref rid="B37" ref-type="bibr">37</xref></sup> using single-pill combinations,<sup><xref rid="B38" ref-type="bibr">38</xref></sup> encouraging patients to monitor their BP at home,<sup><xref rid="B39" ref-type="bibr">39</xref></sup> and fostering a close relationship between healthcare professionals and patients,<sup><xref rid="B40" ref-type="bibr">40</xref></sup> can contribute to the success of this strategy.</p><p>Another approach to improving patient adherence is to involve patients in the decision-making process. Using cardiovascular risk prediction calculators, it is possible to determine the individual probability of cardiovascular events over the next 10 years.<sup>41</sup> Based on this estimate, patients can be informed about the real meaning of an additional BP reduction and, consequently, future cardiovascular risk, also considering the possible disadvantages (adverse events, cost, adherence, etc.). This promotes a better understanding of the proposed strategy as a whole, as well as the strategy&#x02019;s permanent effects.</p><p>There are some limitations to this systematic review and meta-analysis. First, there is an understandable heterogeneity between the characteristics of the various studies on the topic. They differ in several aspects, including the definitions of intensive antihypertensive treatment goals, participants&#x02019; mean age, BP measurement methods, and the baseline cardiovascular risk of the patients included, among others. Second, the studies have limited information regarding the progression of kidney disease in patients already affected by chronic kidney disease. Although this was a predefined clinical outcome in the protocol, it was not widely investigated in the included studies, which prevents the formulation of definitive conclusions. Finally, the follow-up time of the studies varied between 2 and 5 years, approximately. The treatment time for hypertension is undefined, from the outset, for the total remaining life of the patient with hypertension. Therefore, the clinical effect demonstrated in a limited number of years may be underestimated for a much longer-term clinical strategy.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>Hypertension continues to pose an immense health challenge, with profound implications for cardiovascular morbidity and mortality in the Brazilian population. The findings of this review highlight the benefits of intensive antihypertensive treatment goals, which have been shown to significantly reduce the incidence of major cardiovascular events. However, the decision to adopt more aggressive BP control goals should be individualized, taking into account patient-specific factors such as age, frailty, and risk of adverse events. Moreover, ensuring patient adherence to prescribed medication regimens is crucial to the success of any treatment strategy. By considering potential risks and benefits and involving patients in the final decision-making process, health professionals can optimize the management of hypertension and improve clinical outcomes for patients and health systems.</p></sec></body><back><fn-group><fn fn-type="other"><p><bold>Study association:</bold> This study is not associated with any thesis or dissertation work.</p></fn><fn fn-type="other"><p><bold>Ethics approval and consent to participate:</bold> This article does not contain any studies with human participants or animals performed by any of the authors.</p></fn><fn fn-type="supplementary-material"><p><bold>* Supplemental Materials:</bold> For additional information, <inline-supplementary-material xlink:href="0066-782X-abc-122-3-e20240761-suppl01-en.pdf" id="d67e4661" content-type="local-data">please click here</inline-supplementary-material>.</p></fn><fn fn-type="financial-disclosure"><p><bold>Sources of funding:</bold> There were no external funding sources for this study.</p></fn></fn-group></back></sub-article></article>